112 results on '"C. Maugard"'
Search Results
2. Clinical performance evaluation of Elecsys HIV Duo, Anti-HCV II, HBsAg II, Anti-HBc II, and Syphilis assays for routine screening of first-time blood donor samples at a French blood donation center
- Author
-
J. Relave, M. Klinkicht, C. Maugard, and C. Fabra
- Subjects
HBsAg ,Clinical Biochemistry ,Human immunodeficiency virus (HIV) ,Blood Donors ,HIV Infections ,medicine.disease_cause ,Roche Diagnostics ,Sensitivity and Specificity ,Antigen ,medicine ,Humans ,Syphilis ,Hepatitis B Surface Antigens ,biology ,business.industry ,Biochemistry (medical) ,Hematology ,Hepatitis C ,Assay sensitivity ,Hepatitis B ,medicine.disease ,Virology ,biology.protein ,Antibody ,business - Abstract
Objectives Implementing fully automated analyzers has become a crucial safety step in blood donation centers. The Elecsys® assays were evaluated on the cobas e 801 module (Roche Diagnostics) for routine first-time blood donor screening. Materials & Methods Five Elecsys infectious disease assays were tested on the cobas e 801 module at Etablissement Francais du Sang, Montpellier, France (March–April 2018). The performance of Elecsys HIV Duo, Anti-HCV II, HBsAg II, Anti-HBc II, and Syphilis assays was compared with PRISM HIV O Plus, HCV, HBsAg, HBcore, and newbio pk TPHA assays (specificity analyses)/ARCHITECT Syphilis TP (sensitivity analyses), respectively. Specificity was determined in residual fresh serum samples from unselected first-time blood donors (n ≥ 5195 per parameter). Elecsys assay sensitivity was tested using 30 preselected, positively characterized samples per assay and compared with archived routine testing data for comparator assays. Results Across all parameters, specificities for repeatedly reactive samples ranged from 99.81–100.00% for Elecsys assays and 99.71–99.98% for comparator assays. Sensitivities of Elecsys and comparator assays were the same for hepatitis C (85.19%), hepatitis B surface antigen (70.00%), hepatitis B core antigen antibodies (100.00%), and syphilis (100.00%). The sensitivity of the Elecsys HIV Duo assay was higher than the comparator assay (83.33% vs. 76.67%), but the difference was not statistically significant. Conclusions Elecsys infectious disease assays on the cobas e 801 module demonstrated high specificity and sensitivity for screening first-time blood donor samples, and were comparable with other commercially available assays. The Elecsys assays are reliable tests for screening blood donations.
- Published
- 2022
- Full Text
- View/download PDF
3. Syndrome de Muir-Torre chez un patient atteint de maladie de Waldenström
- Author
-
Bernard Cribier, B. Lioure, C. Maugard, F. Bourlond, C. Velter, C. Wettlé, and Dan Lipsker
- Subjects
Gynecology ,030207 dermatology & venereal diseases ,03 medical and health sciences ,medicine.medical_specialty ,0302 clinical medicine ,Muir–Torre syndrome ,business.industry ,030220 oncology & carcinogenesis ,Medicine ,Dermatology ,business ,medicine.disease - Abstract
Resume Introduction Le syndrome de Muir-Torre (SMT), variante a expression cutanee du syndrome de Lynch, est une predisposition hereditaire a la survenue de tumeurs cutanees et de neoplasies digestives et gynecologiques, dont la transmission s’effectue sur un mode autosomique dominant. Il est associe a des mutations sur les genes codant pour des proteines du systeme de reparation des mesappariements de l’ADN. Observation Nous rapportons le cas d’un patient atteint d’une maladie de Waldenstrom depuis l’âge de 50 ans et qui a developpe a partir de 65 ans des tumeurs sebacees (5 adenomes sebaces, 1 sebaceome, 1 carcinome sebace) et des lesions coliques (4 adenomes). Le phenotype clinique etait compatible avec un SMT. L’analyse somatique effectuee dans une tumeur sebacee a montre une instabilite des microsatellites avec perte d’expression de MSH2 et MSH6 mais l’analyse genetique constitutionnelle n’a trouve aucune mutation germinale connue pour etre deletere. Discussion Ce cas remarquable pose plusieurs problemes, dont l’association eventuelle entre le STM et la maladie de Waldenstrom qui est discutee ici.
- Published
- 2016
- Full Text
- View/download PDF
4. [Muir-Torre syndrome associated with Waldenstrom's macroglobulinemia]
- Author
-
C, Velter, F, Bourlond, C, Wettle, B, Lioure, D, Lipsker, C, Maugard, and B, Cribier
- Subjects
Adenoma ,Male ,Muir-Torre Syndrome ,Carcinoma ,Colonic Neoplasms ,Humans ,Microsatellite Instability ,Sebaceous Gland Neoplasms ,Waldenstrom Macroglobulinemia ,Aged - Abstract
Muir-Torre syndrome (MTS), a cutaneous variant of Lynch syndrome, consists of hereditary predisposition to cutaneous tumours and gastrointestinal and gynaecological neoplasms, with autosomal dominant transmission. It is associated with mutations in genes coding for proteins in the DNA mismatch repair system.Herein, we report a case of a male patient presenting Waldenstrom's macroglobulinemia since the age of 50 and which, after the age of 65 years, developed into sebaceous tumours (5 sebaceous adenomas, 1 sebaceoma, 1 sebaceous carcinoma) and colonic lesions (4 adenomas). The clinical phenotype was consistent with MTS. Somatic analysis carried out on one sebaceous tumour showed instability of the microsatellites with loss of expression of MSH2 and MSH6 although constitutional genetic analysis showed no germline mutations known to be harmful.This noteworthy case raises a number of questions, including the possibility of association between STM and Waldenstrom's macroglobulinemia, which is discussed herein.
- Published
- 2016
5. Neurological Adverse Side-Effects Induced by Cloxacillin
- Author
-
L. Hary, F. Marçon, M. Andréjak, Henri Masson, C. Maugard, and A.S. Lemaire-Hurtel
- Subjects
Pharmacology ,Cloxacillin ,business.industry ,Pharmacology toxicology ,medicine ,Pharmacology (medical) ,Toxicology ,business ,Adverse effect ,medicine.drug - Published
- 2008
- Full Text
- View/download PDF
6. HIGH GRADE GLIOMAS AND DIPG
- Author
-
C. F. Classen, D. William, M. Linnebacher, A. Farhod, W. Kedr, B. Elsabe, S. Fadel, S. Van Gool, S. De Vleeschouwer, C. Koks, A. Garg, M. Ehrhardt, M. Riva, P. Agostinis, N. Graf, T.-W. Yao, Y. Yoshida, J. Zhang, T. Ozawa, D. James, T. Nicolaides, R. Kebudi, F. B. Cakir, O. Gorgun, F. Y. Agaoglu, E. Darendeliler, A. Al-Kofide, E. Al-Shail, Y. Khafaga, H. Al-Hindi, M. Dababo, A. U. Haq, M. Anas, M. G. Barria, K. Siddiqui, M. Hassounah, M. Ayas, S. V. van Zanten, M. Jansen, D. van Vuurden, M. Huisman, D. Vugts, O. Hoekstra, G. van Dongen, G. Kaspers, J. Cockle, E. Ilett, K. Scott, A. Bruning-Richardson, S. Picton, S. Short, A. Melcher, M. Benesch, M. Warmuth-Metz, A. O. von Bueren, M. Hoffmann, T. Pietsch, R.-D. Kortmann, M. Eyrich, S. Rutkowski, M. C. Fruhwald, J. Faber, C. Kramm, M. Porkholm, L. Valanne, T. Lonnqvist, S. Holm, B. Lannering, P. Riikonen, D. Wojcik, A. Sehested, N. Clausen, A. Harila-Saari, E. Schomerus, H. K. Thorarinsdottir, P. Lahteenmaki, M. Arola, H. Thomassen, U. M. Saarinen-Pihkala, S.-M. Kivivuori, P. Buczkowicz, C. Hoeman, P. Rakopoulos, S. Pajovic, A. Morrison, E. Bouffet, U. Bartels, O. Becher, C. Hawkins, T. W. A. Gould, C. V. Rahman, S. J. Smith, D. A. Barrett, K. M. Shakesheff, R. G. Grundy, R. Rahman, N. Barua, D. Cronin, S. Gill, S. Lowisl, A. Hochart, C.-A. Maurage, N. Rocourt, M. Vinchon, O. Kerdraon, F. Escande, J. Grill, V. K. Pick, P. Leblond, G. Burzynski, T. Janicki, S. Burzynski, A. Marszalek, N. Ramani, W. Zaky, G. Kannan, A. Morani, D. Sandberg, L. Ketonen, O. Maher, F. Corrales-Medina, H. Meador, S. Khatua, M. Brassesco, L. Delsin, G. Roberto, C. Silva, L. Ana, E. Rego, C. Scrideli, K. Umezawa, L. Tone, S. J. Kim, C.-Y. Kim, I.-A. Kim, J. H. Han, B.-S. Choi, H. S. Ahn, H. S. Choi, F. Haque, R. Layfield, R. Grundy, L. Gandola, E. Pecori, V. Biassoni, E. Schiavello, C. Chiruzzi, F. Spreafico, P. Modena, F. Bach, E. Pignoli, M. Massimino, M. Drogosiewicz, B. Dembowska-Baginska, E. Jurkiewicz, I. Filipek, M. Perek-Polnik, E. Swieszkowska, D. Perek, S. Bender, D. T. Jones, H.-J. Warnatz, B. Hutter, T. Zichner, J. Gronych, A. Korshunov, R. Eils, J. O. Korbel, M.-L. Yaspo, P. Lichter, S. M. Pfister, S. Yadavilli, O. J. Becher, M. Kambhampati, R. J. Packer, J. Nazarian, F. C. Lechon, L. Fowkes, K. Khabra, L. M. Martin-Retortillo, L. V. Marshall, S. Vaidya, D.-M. Koh, M. O. Leach, A. D. Pearson, S. Zacharoulis, D. Schrey, G. Barone, E. Panditharatna, M. Stampar, A. Siu, H. Gordish-Dressman, J. Devaney, E. I. Hwang, A. H. Chung, R. K. Mittapalli, W. F. Elmquist, D. Castel, M.-A. Debily, C. Philippe, N. Truffaux, K. Taylor, R. Calmon, N. Boddaert, L. Le Dret, P. Saulnier, L. Lacroix, A. Mackay, C. Jones, S. Puget, C. Sainte-Rose, T. Blauwblomme, P. Varlet, N. Entz-Werle, C. Maugard, G. Bougeard, A. Nguyen, M. P. Chenard, A. Schneider, M. P. Gaub, M. Tsoli, A. Vanniasinghe, P. Luk, P. Dilda, M. Haber, P. Hogg, D. Ziegler, S. Simon, M. Monje, K. Gurova, A. Gudkov, M. Zapotocky, M. Churackova, B. Malinova, J. Zamecnik, M. Kyncl, M. Tichy, A. Puchmajerova, J. Stary, D. Sumerauer, J. Boult, M. Vinci, L. Perryman, G. Box, A. Jury, S. Popov, W. Ingram, S. Eccles, S. Robinson, S. Emir, H. A. Demir, C. Bayram, F. Cetindag, G. B. Kabacam, A. Fettah, J. Li, Y. Jamin, C. Cummings, J. Bamber, R. Sinkus, M. Nandhabalan, L. Bjerke, A. Burford, A. von Bueren, M. Baudis, P. Clarke, I. Collins, P. Workman, N. Olaciregui, J. Mora, A. Carcaboso, A. Bullock, M. Alonso, C. de Torres, O. Cruz, E. Pencreach, F. M. Moussalieh, D. Guenot, I. Namer, I. Pollack, R. Jakacki, L. Butterfield, R. Hamilton, A. Panigrahy, D. Potter, A. Connelly, S. Dibridge, T. Whiteside, H. Okada, S. Ahsan, E. Raabe, M. Haffner, K. Warren, M. Quezado, L. Ballester, C. Eberhart, F. Rodriguez, C. Ramachandran, S. Nair, K.-W. Quirrin, Z. Khatib, E. Escalon, S. Melnick, M. Hofmann, I. Schmid, T. Simon, E. Maass, A. Russo, G. Fleischhack, M. Becker, H. Hauch, A. Sander, C. Grasso, N. Berlow, L. Liu, L. Davis, E. Huang, P. Woo, Y. Tang, A. Ponnuswami, S. Chen, Y. Huang, M. Hutt-Cabezas, L. Dret, P. Meltzer, H. Mao, J. Abraham, M. Fouladi, M. N. Svalina, N. Wang, E. Hulleman, X.-N. Li, C. Keller, P. T. Spellman, R. Pal, M. H. A. Jansen, A. C. P. Sewing, T. Lagerweij, D. J. Vuchts, D. G. van Vuurden, V. Caretti, P. Wesseling, G. J. L. Kaspers, K. Cohen, M. Pearl, M. Kogiso, L. Zhang, L. Qi, H. Lindsay, F. Lin, S. Berg, J. Muscal, N. Amayiri, U. Tabori, B. Campbel, D. Bakry, M. Aronson, C. Durno, S. Gallinger, D. Malkin, I. Qaddumi, A. Musharbash, M. Swaidan, M. Al-Hussaini, S. Shandilya, C. McCully, R. Murphy, S. Akshintala, D. Cole, R. P. Macallister, R. Cruz, B. Widemann, R. Salloum, A. Smith, M. Glaunert, A. Ramkissoon, S. Peterson, S. Baker, L. Chow, J. Sandgren, S. Pfeifer, S. Popova, I. Alafuzoff, T. D. de Stahl, S. Pietschmann, M. J. Kerber, I. Zwiener, G. Henke, K. Muller, N. Y.-F. Sieow, R. H. M. Hoe, A. M. Tan, M. Y. Chan, S. Y. Soh, K. Burrell, Y. Chornenkyy, M. Remke, B. Golbourn, M. Barzczyk, M. Taylor, J. Rutka, P. Dirks, G. Zadeh, S. Agnihotri, R. Hashizume, Y. Ihara, N. Andor, X. Chen, R. Lerner, X. Huang, M. Tom, D. Solomon, S. Mueller, C. Petritsch, Z. Zhang, N. Gupta, T. Waldman, A. Dujua, J. Co, F. Hernandez, D. Doromal, M. Hegde, A. Wakefield, V. Brawley, Z. Grada, T. Byrd, K. Chow, S. Krebs, H. Heslop, S. Gottschalk, E. Yvon, N. Ahmed, G. Cornilleau, J. Paulsson, F. Andreiuolo, L. Guerrini-Rousseau, B. Geoerger, G. Vassal, A. Ostman, D. W. Parsons, L. R. Trevino, F. Gao, X. Shen, O. Hampton, M. Kosigo, P. A. Baxter, J. M. Su, M. Chintagumpala, R. Dauser, A. Adesina, S. E. Plon, D. A. Wheeler, C. C. Lau, G. Gielen, A. z. Muehlen, R. Kwiecien, J. Wolff, R. R. Lulla, J. Laskowski, S. Goldman, V. Gopalakrishnan, J. Fangusaro, M. Kieran, A. Fontebasso, S. Papillon-Cavanagh, J. Schwartzentruber, H. Nikbakht, N. Gerges, P.-O. Fiset, D. Bechet, D. Faury, N. De Jay, L. Ramkissoon, A. Corcoran, D. Jones, D. Sturm, P. Johann, T. Tomita, M. Nagib, A. Bendel, L. Goumnerova, D. C. Bowers, J. R. Leonard, J. B. Rubin, T. Alden, A. DiPatri, S. Browd, S. Leary, G. Jallo, M. D. Prados, A. Banerjee, A.-S. Carret, B. Ellezam, L. Crevier, A. Klekner, L. Bognar, P. Hauser, M. Garami, J. Myseros, Z. Dong, P. M. Siegel, W. Gump, K. Ayyanar, J. Ragheb, M. Krieger, E. Kiehna, N. Robison, D. Harter, S. Gardner, M. Handler, N. Foreman, B. Brahma, T. MacDonald, H. Malkin, S. Chi, P. Manley, P. Bandopadhayay, L. Greenspan, A. Ligon, S. Albrecht, K. L. Ligon, J. Majewski, N. Jabado, F. Cordero, K. Halvorson, I. Taylor, M. Hutt, M. Weingart, A. Price, M. Kantar, S. Onen, S. Kamer, T. Turhan, O. Kitis, Y. Ertan, N. Cetingul, Y. Anacak, T. Akalin, Y. Ersahin, G. Mason, C. Ho, F. Crozier, G. Vezina, R. Packer, E. Hwang, S. Gilheeney, N. Millard, K. DeBraganca, Y. Khakoo, K. Kramer, S. Wolden, M. Donzelli, C. Fischer, M. Petriccione, I. Dunkel, S. Afzal, A. Fleming, V. Larouche, S. Zelcer, D. L. Johnston, M. Kostova, C. Mpofu, J.-C. Decarie, D. Strother, L. Lafay-Cousin, D. Eisenstat, C. Fryer, J. Hukin, M. Hsu, J. Lasky, T. Moore, L. Liau, T. Davidson, R. Prins, T. Hassal, J. Baugh, J. Kirkendall, R. Doughman, J. Leach, B. Jones, L. Miles, D. Hargrave, T. Jacques, S. Savage, D. Saunders, R. Wallace, B. Flutter, D. Morgenestern, E. Blanco, K. Howe, M. Lowdell, E. Samuel, A. Michalski, J. Anderson, Y. Arakawa, K. Umeda, K.-i. Watanabe, T. Mizowaki, M. Hiraoka, H. Hiramatsu, S. Adachi, T. Kunieda, Y. Takagi, S. Miyamoto, S. Venneti, M. Santi, M. M. Felicella, L. M. Sullivan, I. Dolgalev, D. Martinez, A. Perry, P. W. Lewis, D. C. Allis, C. B. Thompson, and A. R. Judkins
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,03 medical and health sciences ,Abstracts ,0302 clinical medicine ,Text mining ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,Neurology (clinical) ,business ,030217 neurology & neurosurgery - Published
- 2014
7. Prevalence of germline mutations of h MLH1 , h MSH2 , h PMS1 , h PMS2 , and h MSH6 genes in 75 French kindreds with nonpolyposis colorectal cancer
- Author
-
Q. Wang, C. Lasset, F. Desseigne, J.-C. Saurin, C. Maugard, C. Navarro, E. Ruano, L. Descos, V. Trillet-Lenoir, J.-F. Bosset, and A. Puisieux
- Subjects
Genetics ,Genetics (clinical) - Published
- 1999
- Full Text
- View/download PDF
8. Marker segregation information in breast/ovarian cancer genetic counseling: Is it still useful?
- Author
-
C. Maugard, François Eisinger, D. Lanoë, S. De Resende, Olga M. Sinilnikova, C. Girodet, Sabine Pagès, Michel Longy, Catherine Bonaïti-Pellié, Dominique Stoppa-Lyonnet, Hagay Sobol, L. Essioux, and Y J Bignon
- Subjects
Linkage (software) ,Genetics ,endocrine system diseases ,Genetic counseling ,Biology ,medicine.disease ,Mutation Carrier ,Genetic marker ,Mutation (genetic algorithm) ,Genetic predisposition ,medicine ,skin and connective tissue diseases ,Ovarian cancer ,Gene ,Genetics (clinical) - Abstract
The use of mutation screening of BRCA1 and BRCA2 genes as a genetic test is still to a certain extent limited and the oncogeneticist may want to use complementary approaches to identify at-risk individuals. In a series of 23 families with at least three breast or ovarian cancer cases, screened for mutations at BRCA1 and BRCA2 and typed for markers at both loci, we investigated the usefulness of marker segregation information at two levels: 1) to what extent can the indirect approach identify the mutation carrier status of screened cases and their first-degree relatives, and 2) in what way does it help to identify the gene implicated in a family in which neither BRCA1 nor BRCA2 mutation has been detected? Using the indirect approach, the carrier status of the screened case could be determined with quasi certainty in three families and with a high probability in eight families. This status could be inferred in unaffected first-degree relatives as almost certain in one family and as highly probable in six families. Fourteen mutations were found concurrently in our series. Among the nine mutation-negative families, we were able to conclude that a BRCA1 mutation most probably segregated in one and that a mutation other than BRCA1 and BRCA2 was probably involved in two families. Our results show that, in small families, little help is to be expected from linkage data and mutation screening is the only way of identifying the origin of a genetic predisposition in a family. Marker segregation information may be useful in some large breast/ovarian cancer families in which no BRCA1 or BRCA2 mutation has been detected.
- Published
- 1998
- Full Text
- View/download PDF
9. French multicentric evaluation of mdr1 gene expression by RT-PCR in leukemia and solid tumours. Standardization of RT-PCR and preliminary comparisons between RT-PCR and immunohistochemistry in solid tumours
- Author
-
Jacques Robert, C Maugard, Pierre Verrelle, Ph Genne, Jean-Pierre Marie, A Clary, M. Raphael, P. Colosetti, JL Merlin, J Charrier, F. Pinguet, L Danel-Moore, B. Richard, Sylvie Chevillard, M. Mousseau, F Calvo, C. Delvincourt, F Finat-Duclos, V Quillien, Pierre Validire, Anne-Marie Faussat, JC Kouyoumdjian, C Bayle, Ph Vielh, P Decrémoux, Lacave R, C Bonnal, Jean Bénard, J. Boutonnat, A Kataki, and V. Barbu
- Subjects
Cancer Research ,Pathology ,medicine.medical_specialty ,business.industry ,Hematology ,Drug resistance ,Molecular biology ,Reverse transcriptase ,law.invention ,Multiple drug resistance ,Real-time polymerase chain reaction ,Oncology ,law ,Gene expression ,Medicine ,Immunohistochemistry ,Northern blot ,business ,Polymerase chain reaction - Abstract
Since there is no consensus on the techniques for multidrug resistance (MDR) phenotype evaluation, many discrepancies concerning the importance and frequency of mdr1 gene expression in leukemias and solid tumors are observed in the literature. In order to establish an inter-laboratory consensus in France, a multicenter study was carried out to propose further guidelines for MDR phenotype evaluation. The techniques used by the 38 laboratories participating in the trial were: immunodetection (immunohisto and/or cytochemistry, flow cytometry), functional tests, reverse transcription-polymerase chain reaction (RT-PCR) or Northern blot. We present the results obtained by 19 laboratories concerning the measurement of mdr1 gene expression assessed by RT-PCR or Northern blot in: (1) 19 samples of tumor cells obtained from leukemic patients; (2) six solid tumor samples obtained at surgery; (3) eight cell lines exhibiting variable levels of resistance, and; (4) 10 preparations of RNA and of cDNA obtained from solid tumors. Standardization of the RT-PCR technique and preliminary results comparing RT-PCR with immunohistochemistry in solid tumors are also reported.
- Published
- 1997
- Full Text
- View/download PDF
10. Attitudes towards cancer predictive testing and transmission of information to the family
- Author
-
Hagay Sobol, Françoise Chabal, M. Machelard-Roumagnac, Philippe Vennin, Claire Julian-Reynier, P Orsoni, C. Maugard-Louboutin, D Serin, B Blanc, Y J Bignon, François Eisinger, Y. Aurran, and Catherine Noguès
- Subjects
Adult ,medicine.medical_specialty ,Genetic counseling ,Breast Neoplasms ,Disclosure ,Anxiety ,Risk Assessment ,Breast cancer ,Risk Factors ,Genetics ,medicine ,Humans ,Family ,Genetic Testing ,First-degree relatives ,Risk factor ,Predictive testing ,Genetics (clinical) ,Genetic testing ,medicine.diagnostic_test ,business.industry ,Cancer ,medicine.disease ,Pedigree ,Family medicine ,Female ,France ,medicine.symptom ,business ,Attitude to Health ,Research Article - Abstract
Before the organisation of breast cancer predictive testing in France, consultands' attitudes towards this kind of testing and towards passing on information about the family cancer risk to their relatives were investigated. This survey was carried out from January 1994 to January 1995 at six specialised cancer genetic clinics located in different parts of France Female consultands who were first degree relatives of cancer patients and who had at least one case of breast cancer in their family, affecting either themselves or a first degree relative or both, participated in this study. Among the 248 eligible consultands attending the clinics during the study period, 84.3% answered a post-consultation questionnaire. Among the 209 respondents, 40.7% (n = 85) were cancer patients and 59.3% (n = 124) were healthy consultands. A high consensus in favour of genetic testing was noted, since 87.7% of the sample stated that they would ask for breast cancer gene testing if this test became available. The underlying assumption of 96.6% of the women was that their health surveillance would be improved after a positive test. A high awareness of the anxiety that would be generated in a family after a positive result was observed and found to be associated (p < 0.05) with the anxiety and depressive profiles of the patients. Half of the healthy respondents said they would not change their attitude towards screening if the results of predictive testing turned out to be negative. Only 13.7% of the 161 patients who stated that the oncogeneticists asked them to contact their relatives firmly refused to do so, mainly because of difficult family relationships.
- Published
- 1996
- Full Text
- View/download PDF
11. Cancer genetics clinics: Target population and consultees' expectations
- Author
-
Hagay Sobol, Y J Bignon, Claire Julian-Reynier, M. Mercuri, M. Machelard-Roumagnac, S. Versini, François Eisinger, Françoise Chabal, Catherine Noguès, Y. Aurran, Philippe Vennin, C. Maugard-Louboutin, and Daniel Serin
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Pediatrics ,Outpatient Clinics, Hospital ,Patients ,Genetics, Medical ,Population ,Social epidemiology ,Medical Oncology ,Risk Assessment ,Humans ,Cancer Family ,Medicine ,education ,Referral and Consultation ,education.field_of_study ,Cancer prevention ,business.industry ,Cancer ,medicine.disease ,Socioeconomic Factors ,Oncology ,Cancer genetics ,Family medicine ,Medical genetics ,Female ,France ,business ,Risk assessment - Abstract
The aim of this study was to determine in healthy consultees attending cancer genetics clinics their risk status, their pathways leading to the clinics, their expectations and perception of cancer risk. In 1994, the consultees at six French centres completed a questionnaire before their first oncogenetic consultation. The oncogeneticists subsequently filled in a standardised form giving their risk assessment. Among the 206 healthy consultees, 91.3% were women, 92.2% had at least one cancer-affected first-degree relative and 73% had a “cancer family risk” as assessed by the oncogeneticist. Sixty-nine per cent of the consultees were referred to the clinics by a physician, 10.4% by their family and 18.8% on their own initiative: 83.5% of the sample perceived their family risk of cancer as being high and this belief was confirmed in 74.3% of the cases studied by the oncogeneticist. The families of self-referred consultees were less often at risk than those of consultees referred by a physician or by their family ( P = 0.012). The majority (78%) expected to be informed about cancer prevention and screening, and this expectation depended on the consultee's level of education ( P = 0.001). This study shows that medical pathways are more effective than the media as a means of reaching the members of the general population who are genuinely at risk, and shows that fuller information about prevention needs to be provided at cancer genetic consultations.
- Published
- 1996
- Full Text
- View/download PDF
12. Fourth meeting of the European Neurological Society 25–29 June 1994 Barcelona, Spain
- Author
-
H. Hattig, C. Delli Pizzi, M. C. Addonizio, Michelle Davis, A. R. Giovagnoli, L. Florensa, M. Roth, J. de Kruijk, Francisco Lacruz, Ph. Dewailly, A. Toygar, C. Avendano, P.P. De Deyn, J. F. Hurtevent, F. Lomeila, T. W. Wong, Gordon T. Plant, M. Bud, H. J. Willison, DH Miller, D. W. Langdon, R. Cioni, J. Servan, A. Kaygisiz, E. Racadot, D. B. Schens, E. Picciola, L. Falip, C. Bouchard, J. Jotova, A. Jorge-Santamaria, P. Misra, A. Dufour, C. P. Panagopoulos, A. Venneri, B. Sredni, B. Angelard, M. Janelidze, M. Carreno, J. Obenberger, J. Pouget, H. W. Moser, R. Kaufmann, J. A. Molina, D. Linden, A. Martin Urda, E. Uvestad, A. Krone, J. P. Cochin, J. Mallecourt, A. Cambon-Thomsen, K. Violleau, P. Osschmann, A. M. Durocher, E. Bussaglia, D. M. Danielle, H. Efendi, C. Van Broeckhoven, K. G. Jordan, W. Rautenberg, C. Iniguez, J. M. Delgado, Graham Watson, M. Lawden, Gareth J. Barker, K. Stiasny, James T. Becker, G. Campanella, E. Peghi, A. Poli, A. Haddad, T. Yamawaki, Giacomo P. Comi, S. Sotgiu, B. Ersmark, A. Pomes, M. Ziegler, P. Ferrante, P. Ruppi, H. KuÇukoglu, R. Bouton, U. K. Rinne, P. Vieregge, M. Dary, P. Giunti, Peter J. Goadsby, S. Jung, E. Secor, A. Steinberg, N. Vila, M. A. Hernandez, M. Cursi, A. Enqelhardt, A. Engelhardt, J. Veitch, F. Di Silverio, F. Arnaud, B. Neundörfer, R. Brucher, Dominique Caparros-Lefebvre, B. Meyer, Marianne Dieterich, M. H. Snidaro, R. Gomez, R. Cerbo, M. Ragno, J. M. Vance, S. Nemni, A. Caliskan, F. Barros, I. Velcheva, D. Ceballos-Baumann, V. Barak, A. Avila, N. Antonova, F. Resche, S. Pappata, L. Varela, S. R. Silveira Santos, A. Cammarota, L. Naccache, Y. Nara, E. Tournier-Lasserves, R. Mobner, T. Chase, A. Ensenyat, J. Ulrich, G. Giegerich, M. Rother, M. Revilla, N. Nitschke, K. Honczarenko, E. Basart Tarrats, J. Blin, B. Jacob, J. Santamaria, S. Knezevic, J. L. Castillo, M. Antem, J. Colomer, O. Busse, Didier Hannequin, S. Carrier, J. B. Ruidavets, C. Rozman, J. Bogoussslavsky, J. Pascual Calvet, E. Monros, J. M. Polo, M. Zucconl, Javier Muruzabal, R. R. Allen, R. Rivolta, K. Haugaard, A. Nespolo, K. Hoang-Xuang, G. Bussone, T. Avramidis, E. Corsini, Christiana Franke, T. Vinogradova, H. Boot, K. Vestergaard, G. H. Jansen, N. Argentino, M. Raltzig, W. Linssen, Mark B. Pepys, P. Roblot, L. Lauritzen, E. Fainardi, D. Morin, T. X. Arbizu Urdiain, J. Wollenhaupt, S. Bostantjopoulou, G. Pavesi, A. D. Forman, Giovanni Fabbrini, D. Jean, J. J. Archelos, M. I. Blanchs, M. Del Gobbo, Anna Carla Turconi, Ch. Derouesné, Elio Scarpini, A. Visbeck, P. Castejon, J. P. Renou, F. Mounier-Vehier, G. Potagas, Ch. Duyckaerts, A. Filla, R. Schneider, G. Ronen, K. Nagata, J. P. Vedel, A. Henneberg, G. van Melle, C. Baratti, H. Knott, M. C. Prevett, A. Bes, B. Metin, Jos V. Reempts, L. Martorell, Mefkure Eraksoy, H. O. Handwerker, D. S. Younger, O. Oktem, D. Frongillo, C. Soriano-Soriano, L. Niehaus, F. Zipp, A. Tartaro, S Newman, R. H. Browne, P. Davous, R. Sanchez, M. Muros, M. E. Kornhuber, A. Lavarone, M. Mohr, M. R. Garcia, S. Russell, H. Kellar-Wood, M. R. Tola, B. Ostermeyer, Ch. Tzekov, K. Sartor, E. B. Ringelstein, P. P. Gazzaniga, Paul Krack, H. Fidaner, H. Rico, T. Dbaiss, F. Alameda, E. Torchiana, L. Rumbach, I. Charques, J. M. Bogaard, C. D. Frith, L. J. Rappelle, R. Brenner, A. Joutel, K. Fuxe, G. HÄcker, M. J. Blaser, J. Valls-SolÇ, G. Ulm, M. Alberdi, A. Bock, F. W. Bertelsmann, U. Wieshmann, J. Visa, J. R. Lupski, D. D'Amico, L. M. P. Ramos, A. A. Vanderbark, R. Horn, M. Warmuth, Dietmar Kühne, Mark S. Palmer, C. Ehrenheim, E. Canga, S. Viola, O. Scarpino, P. Naldi, R. Almeida, A. A. Raymond, J. Gamez, Stephan Arnold, A. DiGiovanni, J. Dalmau, C. C. Chari, H. F. Beer, J. C. Koetsier, J. Iriarte, E. Yunis, J. Casadevall, E. Le Guern, E. Stenager, S. R. Benbadis, J. M. Warter, F. Burklin, I. Theodorou, L. Johannesen, G. A. Graveland, X. Leclerc, I. Vecchio, L. Ozelius, G. Nicoletti, R. K. Gherardi, E. Esperet, M. L. Delodovici, F. Cattin, F. Paiau, Giorgio Sacilotto, C. A. J. Broere, D. Chavdarov, J. P. Willmer, C. H. Hawkes, Th. Naegele, E. Ellie, E. Dartigues, M. J. Guardiola, S. Hesse, Z. Levic, Marco Rovaris, P. Saugeir-Veber, B. A. Yaqub, H. F. Durwen, R. Larumbe, J. Ballabrina, M. Sendtner, J. Röther, M. Horstink, C. Kluglein, M.P. Montesi, H. Apaydin, J. Montoya, E. Waubant, Ch. Verellen-Dunoulin, A. Nicolai, J. Lopez-Delval, R. Lemon, G. Cantinho, E. Granieri, A. Zeviani, Wolfgang H. Oertel, U. Ficola, V. Di Piero, V. Fragola, K. Sabev, M. V. Guitera, I. Turki, F. Bolgert, P. Ingrand, J. M. Gobernado, L. M. E. Grimaldi, S. Baybas, B. Eymard, Y. Rolland, Y. Robitaille, Ta. Pampols, P. J. Koehler, A. Carroacedo, J. Vilchez, S. Di Vittorio, I. R. Rise, T. Nagy, M. Kuffner, E. Palazzini, A. Ott, J. Pruim, T. X. Arbizu, E. Manetti, C. Cervera, S. Felber, G. Gursoy, J. Scholz, G. A. Buscaino, M. S. Chen, A. Pascual, J. Hazan, J. U. Gajda, J. G. Cea, G. Bottini, G. Damalik, F. Le Doze, G. Bonaldi, J. M. Hew, C. Messina, A. M. Kennedy, J. M. Carney, N. M. F. Murray, M. Parent, M. Koepp, V. Dimova, D. De Leo, K. Jellinger, G. Salemi, S. Mientus, M. L. Hansen, F. Mazzucchelli, J. Vieth, M. Mauri, E. Bartels, L. Johannsen, C. Humphreys, J. Emile, D. N. Landon, E. Kansu, R. Sanchez-Pernaute, Rsj Frackowiak, M. Gonzalez Torres, L. Oller, C. Machedo, J. Kother, M. Billiard, H. Durak, T. Schindler, A. Frank, A. Uncini, A. Sbriccoli, C. Farinas, D. W. Paty, N. Fast, A. T. Zangaladze, A. Kerkhofs, J. M. Pino Garcia, I. De la Fuente, B. Marini, L. Gomez, I. Rubio, Alessandra Bardoni, C. Brodie, P. Acin, U. Sliwka, S. A. Hawkins, S. Tardieu, F. Vitullo, J. M. Pereira Monteino, R. Gagliardi, T. Jezewski, A. Cano, T. Lempert, F. Abad Alegria, G. Rotondo, D. Ince, C. Martinez Parra, Y. Huang, H. Luders, Y. Steinvil, F. G. A. Van Der Meche, R. Bianchi, A. Sanchez, T. Sevilla, J. M. Ketelslegers, A. Domzal-Stryga, M. Pandolfo, M. O. Josse, K. W. Neff, I. Blanco, G. W. Bruyn, O. W. Witte, J. L. Thibault, G. Andersen, J. Pariset, A. Marcone, R. J. M. Lane, A. Hofman, M. Verin, T. Matilla, P. Bedoucha, J. Roche, M. Lai, M. Collard, A. Ugarte, F. Gallecho, D. Silbersweig, C. Kennard, J. P. Azulay, T. W. Ho, P. L. I. Dellemijn, R. Girardello, F. Baas, B. Voss, F. Rozenberg, E. M. Brocker, V. Stanev, A. A. J. Soeterboek, A. Marra, A. Rey, E. Ertem, M. Sawradewicz-Rybak, J. De Keyser, P. Cavallari, F. Proust, Y. Chevalier, H. C. Hansen, D. Leys, C. A. Davie, K. Hoang-Xuan, C. Bairati, H. van Crevel, Thomas T. Warner, B. Bompais, A. Dobbeleir, T Campbell, C. Macko, C. J. M. Klijn, M. Dussallant, T. P. Berlit, W. Rozenbaum, M. J. van den Bent, W. A. Rocca, M. Muller, H. Hundemer, U. Zifko, M. Campera, F. Drislane, D. Ranoux, T. M. Kloss, Anil Kumar, I. Ruolt, C. Bargnani, B. Marescau, N. A. Losseff, S. Notermans, B. Kint, E. T. Burke, C. Aykut, J. Matias Guiu, P. Maquet, T. Drogendijk, M. Leone, K. von Ammon, M. Pepeliarska, C. Prados, L. DiGiamberardino, T. Logtenberg, G. Lenoir, I. Castaldo, Damhaut, M. Radionova, G. Sirabian, R. Navon, Giovanni Antonini, K. Al Moutaery, E. Chamas, R. Schönhuber, M. Giannini, B. Debilly, I. Labatut, H. Henon, J. A. Egido, M. Baudrimont, J. N. Lorenzo, J. E. C. Bromberg, R. Antonacci, J. J. Vilchez, T. Moulin, B. Rautenstrauss, Giovanni Meola, J. Noth, S Mammi, P. Laforet, F. Lopez, C. Gehring, S. Bort, G. Rancurel, D. Decamps, S. Kostadinova, Y. Shapira, B. Neundoerfer, D. Chavrot, M. Solimena, J. P. Salier, W. Deberdt, R. Hoff-Jörgensen, A. Messina, S. Meairs, G. Rosoklija, E. Nelis, I. Bertran, C. Ertekin, J. Lohmeyer, Mitermayer Galvao dos Reis, L. Calo, E. Maccagnano, A. P. Hays, J. Verlooy, M. G. Forno, T. Blanco, L. Bail, Gabriella Silvestri, J. Montero, F. Bertrand, R. T. Ghnassia, C. Besses, T. Sereghy, F. Shalit, G. Bogliun, S. Braghi, St. Baykouchev, C. Franke, A. Lasa, L. C. Archard, J. Kriebel, S. Shaunak, M. Nocito, Alexander Tsiskaridze, E. Manfredini, T. Seigal, David G. Gadian, M. Barlas, J. D. Degos, C. Seeber, J. Caemert, J. L. Mas, R. B. Pepinsky, M. G. D'Angelo, N. Baumann, S. Yorifuji, H. P. Endtz, M. A. Cassatella, R. A. C. Hughes, V. Golzi, A. Bittencourt, A. Ferreira, M. Sanson, C. Alper, M. Vermeulen, M. A. A. van Walderveen, E. Alexiou, C. H. Lucas, M. Fiorelli, Y. N. Debbink, R. Gil, S. Congia, T. Banerjee, J. M. Bouchard, A. N. Pinto, A. Ceballos-Baumann, G. Grollier, P. I. M. Schmitz, M. D. Catata, N. Lahat, N. S. Rao, P. Papathanasopoulos, J. Valls-Solé, D. Claus, G. Schroter, A. Castro, C. Videbaek, R. Martinez Dreke, A. D. Platts, M. Hermesl, A. C. PeÇanha-Martins, M. Cardoso Silva, P. Masnou, M. J. A. Tanner, Ch. Confavreux, B. Mishu, H. Rasmussen, L. Valenciano, Carlo Pozzilli, S. W. Li, V. Salzman, Y. Vashtang, Massimo Franceschi, M. Severo, G. Deuschl, S. Setien, G. Mariani, A. Protti, J. Castillo, M. J. B. Taphoorn, M. Frontali, I. Milonas, D. Decoq, J. A. Navarro, S. Castellvi-Pel, C. Ertikin, M. Urtasun, Y. Lajat, B. E. Kendall, E. Verdu, B. Gueguen, E. Boisen, R. Couderc, A Danek, JM Stevens, F. Nicoli, L. Feltri, M. L. Vazquez-Andre, J. A. Morgan-Hughes, L. D'Angelo, F. Y. Liew, L. F. Pascual, J. Patrignani Ochoa, Vittorio Martinelli, J. Cophignon, L. Zhang, S. Martin, J. F. Meder, H. C. Buschmann, L. Bertin, J. van Gijn, A. Barreiro, A. Cools, C. Leon, A. Berod, E. A. Anllo, E. Zanette, L. Petrov, R. Barona, B. Gallicchio, P. J. Cozzone, N. Diederich, G. Cancel, L. Schelosky, P. Orizaola, K. Yulug, S. Ozer, Valeria A. Sansone, B. Guiraud-Chaumeil, K. Voigt, P. Labauge, M. Eoli, J. Zhu, J. Aguirre, M. Ferrarini, B. Zyluk, E. Planas, A. Cadilha, C. Tortorella, H. Bismuth, C. E. Counsell, A. Laun, A. Ferlini, Rio J. Montalban, N. Biary, L. Becker, M. Fardeau, M. Poloni, V. M. S. de Bruin, C. Fornada, J. Barros, E. Ganzmann, E. Touze, D. Wallach, J. Peila, H. Fujimura, M. T. Iba-Zizen, G. Macchi, C. Villoslada, R. Gouider, Ph. Rondepierre, P. Grummich, P. Chiodi, C. Conte, M. Michels, P. Annunziata, G. Semana, C. Sommer, J. Vajsar, D. Zekin, J. Kulisevsky, David G. Munoz, B. Jacotot, M. Magoni, A. Luxen, T. Garcia-Silva, S. Di Cesare, Christophe Tzourio, M. Gomori, I. Picomell, L. Santoro, F. Villa, Giovanni Pennisi, T. Ribalta, J. M. Molto, L. Marzorati, P. Loiseau, F. Gemignani, A. Gironell, J. Wissel, A. Prusinski, F. Cailloux, P. Villanueva-Hemandez, P. Cozzone, T. Del Ser, J. Sans-Sabrafen, M. Zappia, P. W. A. Willems, G. Tchernia, D. Gardeur, R. Bauer, F. Palomo, H. Metz, S. Lamoureux, C. Chastang, I. Reinhard, A. Goldfarb, S. Harder, Jordi Río, C. Ozkara, E. Tekinsoy, P. Vontobell, J. De Recondo, M. Rabasa, L. Lacomblez, F. Boon, Dgt Thomas, V. Palma, Renato Mantegazza, A. Dervis, M. Nueckel, B. YalÇinerner, I. Duran, G. Dalla Volta, A. Zubimendi, J. Pinheiro, A. Marbini, Xavier Montalban, H. Wekerle, X. Pereira Monteino, F. Crespo, F. Koskas, N. Battistini, C. Ruiz, H. Offner, J. de Pommery, P. Kanovsky, J. Y. Barnett, J. Pardo, G. Tomei, R. Rene, H. M. Lokhorst, P. Thajeb, H. Bilgin, D. McGehee, R. Fahsold, L. Morgante, Katie Sidle, C. Delwaide, M. N. Diaye, P. H. Rice, A. Creange, C. Sabev, K. Stephan, K. WeilBenborn, G. Magnani, L. Grymonprez, F. Cardellach, M. Kaps, N. G. Meco, F. Vega, V. Bonifati, A. Desomer, M. Baldy-Moulinier, G. Kvale, F. J. Authier, B. Yegen, T. Ho, J. M. Rozet, E. A. Cabanis, L. Bruce, L. Ambrosoli, M. A. Petrella, M. Hernandez, P. Timmings, H. B. van der Worp, F. Mahieux, A. Urbano-Marquez, D. A. Krendel, A. A. Garcia, R. Divari, R. Michalowicz, M. R. Piedmonte, M. Bondavalli, M. Zanca, P. F. Ippel, Onofre Combarros, B. Tavitian, E. Hirsch, I. Anastasopoulos, A. Roses, A. Köhler, P. Vienna, V. Timmerman, P. Sergi, F. Cornelio, A. Di Pasquale, R. Verleger, S. Castellvirel, J. Proano, B. van Moll, F. Rubio, W. Hacke, I. Lavenu, L. Zetta, M. W. Tas, N. Bittmann, M. Bonamini, O. R. Hommes, V. Dousset, N. Afsar, S. Belal, R. R. Myers, J. Goes, Giuseppe Vita, E. Clementi, V. G. Karepov, M. Jueptner, A Vincent, P. Emmrich, Th. Heb, A. Caballo, J. Gallego, T. Mokrusch, C. Perla, L. Gebuhrer, O. Titlbach, Alessandro Prelle, A. Czlonkowska, M. Russo, D. Hadjiev, T. S. Chkhikvishvili, M. Oehlschlager, G. Becker, I. Günther, E. N. Stenager, J. Garcia Agundez, J. Casademont, J. Batlle, S. Podobnik-Sarkanji, C. Alonso-Villaverde, B. Delaguillaume, B. Genc, B. Mazoyer, A. Rodriguez-Al-barino, Ch. Hilger, B. Ferrero, R. Price, W. Grisold, L. Fuhry, D. Oulbani, D. Ewing, A. Petkov, W. Walther, A. Gokyigit, John Newsom-Davis, J. Tayot, D. Seliak, G. Pelliccioni, D. Campagne, K. Kessler, F. Boureau, D. Perani, J. P. N'Guyen, N. Tchalucova, B. A. Antin-Ozerkis, C. Lacroix, B. D. Aronovich, I. H. Jenkins, E. A. dos Reis, M. Hortells, H. M. Meinck, H. Ch. Buschmann, S. C. J. M. Jacobs, T. Wetter, P. Creissard, N. Martinez, J. Weidenfeldl, H. J. Sturenburg, G. Damlacik, V. Gracia, J. C. Turpin, A. Pou-Serradell, J. P. Vincent, T. Gagoshidze, U. Ozkutlu, M. McLeod, K. Siegfried, I. Tchaoussoglou, J. Hildebrand, S. Kowalska, M. C. Picot, G. Galardin, L. Crevits, F. Andreetta, S. Larumbe-Lobalde, G. de la Sierra, J. C. Alvarez-Cermeno, R. J. Seitz, P. L. Oey, L. Ptacek, A. M. J. Paans, A. Wirrwar, A. Schmied, J. Uilchez, H. Tounsi, D. Hipola, V. Avoledo, Y. Hirata, P. Vermersch, T. M. Aisonobe, J. Valls-SoIè, H. Staunton, J. Dichgans, R. Karabudak, I. Dones, G. Porta, E. Janssens, Maria Martinez, J. M. Fernandez-Real, R. Villagra, Y. Yoshino, C. Kabus, K. Schimrigk, I. Girard-Buttaz, F. Piccoli, F. Aichner, P. Zuchegna, S. M. Al Deeb, F. Bono, N. Busquets, A. Jobert, Patrizia Ciscato, M. Martin, L. Polman, S. Darbra, V. Le Cam-Duchez, F. Baldissera, B. Baykan-Kurt, D. Guez, M. Bratoeva, H. Matsui, M. Mila, H. Perron, L. Bjorge, G. Husby, Steven T. DeKosky, D. R. Cornblath, J. M. Gabriel, J. J. Poza, Y. Wu, A. Toscano, R. P. Kleyweg, J. Kuhnen, S. O. Confort-Gouny, A. Barcelo, A. M. Conti, C. Fiol, C. Steichen-Wiehn, J. Rodes, M. Cavenaile, C. Vedeler, M. Drlicek, C. Argentino, M. L. Peris, A. Cervello, A. Z. GinaÏ, S. Yancheva, D. Passingham, S. Aoba, D. L. Lopez, T. Rechlin, K. Sonka, L. Grazzi, V. Folnegovic-Smalc, Maurizio Moggio, S. Rivaud, F. G. I. Jennekens, C. H. Hartard, H. Meierkord, G. Stocklin, M. D. Catala, W. C. McKay, E. Salmon, C. Navarro, I. Pastor, L. Canafoglia, M. De Braekeleer, P. K. Thomas, C. Mocellini, C. Pierre-Jerome, M. C. Dalakas, P. Pollak, M. Levivier, Niall Quinn, G. E. Rivolta, Z. Tunca, H. Zeumer, J. Garcia Tena, St. Guily, P. Gaudray, Johannes Kornhuber, V. Petrunjashev, R. Montesanti, R. J. Abbott, H. Petit, G. Kiteva-Trencevska, F. Carletto, C. Ramo, I. M. Pino, P. Beau, G. F. Mennuni, F. Moschian, F. Meneghini, B. Zdziarska, B. Fontaine, C. Stephens, G. Meco, K. Reiners, G. Badlan, M. Sessa, I. Degaey, S. M. Hassan, C. Albani, F. Caroeller, M. Schroeder, G. Savettieri, A. Novelletto, R. Kurita, P. Oschmann, I. Plaza, M. Oliveres, Simone Spuler, A. Molins, M. Schwab, J. R. Kalden, C. P. Gennaula, Y. Baklan, O. Picard, J. M. Léger, B. Mokri, E. Ghidoni, M. Jacob, D. Deplanque, W. JÄnisch, C. De Andres, P. De Deyn, G. Guomundsson, B. Herron, J. Barado, J. L. Gastaut, Guglielmo Scarlato, F. Poron, Nicola Jones, H. Teisserenc, C. P. Hawkins, A. J. Steck, H. C. Chandler, S. Blanc, J. H. Faiss, Jm. Soler Insa, I. Sarova-Ponchas, M. Malberin, A. Sackmann, G. De Vuono, K. Kaiser-Rub, K. Badhia, E. Szwabowska-Orzeszko, S. Ramm, C. Jodice, G. Franck, J. Marta-Moreno, R. Sciolla, C. Fritz, A. Attaccalite, F. Weber, E. Neuman, M. Cannata, A. Rodriguez, I. Nachainkin, R. Raffaele, T. S. Yu, N. Losseff, E. Fabrizio, C. Khati, M. Keipes, M. P. Ortega, M. Ramos-Alvarez, E. Brambilla, A. Tarasov, K. H. Wollinsky, O. B. Paulson, F. Boller, G. Bozzato, H. Wagnur, R. Canton, D. Testa, E. Kutluaye, M. Calopa, D. Smadja, G. Malatesta, F. Baggi, A. Stracciari, G. Daral, G. Avanzini, J. Perret, J. Arenas, P. Boon, I. Gomes, A. Vortmeyer, P. Cesaro, S. Venz, E. Bernd Ringelstein, N. Milani, D. Laplane, P. Seibel, E. Tournier-Lasserve, Alexis Brice, L. Motti, E. Wascher, R. J. Abbot, F. Miralles, A. Turon, P. De Camilli, G. Luz, G. C. Guazzi, S. Tekin, F. Lesoin, T. Kryst, N. Lannoy, F. Gerstenbrand, S. Ballivet, H. A. M. van Diemen, J. Lopez-ArLandis, P. Bell, A. Silvani, M. A. Garcia, S. Vorstrup, D. Langdon, S. Ueno, B. Sander, V. Ozurk, C. Gurses, P. Berlit, J. M. Martinez-Lage, M. Treacy, S. O. Rodiek, S. Cherninkova, J. Grimaud, P. Marozzi, K. Hasert, S. Goldman, S. H. Ingwersen, A. Taghavy, T. Roig, R. Harper, I. Sarova-Pinchas, Anthony H.V. Schapira, R. Lebtahi, A. Vidaller, B. Stankov, D. Link, J. p. Malin, V. Petrova, Ludwig Kappos, J. L. Ochoa, T. Torbergsen, M. Carpo, M. Donato, Simon Shorvon, J. Mieszkowski, J. Perez-Serra, Raymond Voltz, G. Comi, S. Rafique, A. Perez-Sempere, N. Khalfallah, S. Bailleul, M. Borgers, S. Banfi, S. Mossman, A. Laihinen, G. Filippini, R. A. Grunewald, E. Stern, H. D. Herrmann, A. G. Droogan, P. Xue, A. Grilo, L. La Mantia, J. H. J. Wokke, S. Pizzul, Kie Kian Ang, S. Rapaport, W. Szaplyko, B. Romero, P. Brunet, A. Albanese, C. Davie, V. Crespi, F. Birklein, H. Sharif, L. Jose, D. Auer, N. Heye, Martin N. Rossor, C. E. Henderson, M. J. Koepp, J. Rubio, P. L. Baron, S. Mahal, Juha O. Rinne, J. I. Emparanza, S. E. C. Davies, Frederik Barkhof, M. Riva, R. E. Brenner, B. A. Pope, Lemaire, E. Dupont, D. Ulbricht, G. C. Pastorino, R. Retska, E. Chroni, A. Danielli, V. Malashkhia, T. Canet, J. C. Garcia-Valdecasas, J. Serena, R. A. Pfeiffer, B. Wirk, B. Muzzetto, V. Caruso, M. L. Giros, A. Ming Wang, E. L. E. Guern, F. Bille-Turg, Y. Satoh, C. H. Franke, M. Ait-Kaci-Ahmed, D. Genis, T. Pasierski, D. Riva, M. Panisset, A. Chamorro, P.A. van Doorn, S. Schellong, H. Hamer, F. Durif, P. Krauseneck, Y. Bahou, B. A. Pickut, M. Rijnites, H. Nyland, G. Jager, L. L. Serra, A. Rohl, X. P. Li, O. Arena, Hubert Kwieciński, N. Milpied, M. C. Bourdel, S. Assami, L. Law, J. Moszkowski, J. W. Thorpe, M. Aguennouz, R. Martin, D. Hoffmann, P. Morris, A. Destée, D. J. Charron, U. Senin, A. P. SempereE, M. Dreyfus, A. L. Benabid, M. Gomez, S. Heindle, M. C. Morel-Kopp, M. Hennerici, A. I. Santos, M. Djannelidze, N. Artemis, John Collinge, T. Rundek, M. Y. Voloshin, P. de Castro, Th. Wiethege, D. A. S. Compston, D. Schiffer, A. J. Hughes, D. Jimenez, V. Parlato, A. Papadimitriou, J. M. Gergaud, R. Sterzi, J. Arpa, G. de Pinieux, F. Buggle, P. Gimbergues, H. Ruottinen, R. Marzella, W. Koehler, Y. Yurekli, A. Haase, Z. Privorkin, G. K. Harvey, B. Chave, A. J. Grau, E. M. Stadlan, J. List, C. Zorzi, B.W. van Oosten, P. Derkinderen, B. Casati, J. M. Maloteaux, K. Vahedi, W. L. J. van Putten, J. C. Sabourin, D. Lorenzetti, Plenevaux, J. W. B. Moll, A. Morento Fernandez, M. Lema, M. A. Horsfleld, P. De Jongh, S. Gikova, K. Kutluk, Monique M.B. Breteler, P. Saddier, A. Berbinschi, R. E. Cull, P. Echaniz, H. Kober, C. Minault, V. Kramer, A. L. Edal, S. Passero, T. Eckardt, K. E. Davies, A. Salmaggi, R. Kaiser, A. A. Grasso, Claudio Mariani, G. Egersbach, Hakan Gurvit, O. Dereeper, C. Vital, L. Wrabetz, A. Vecino, M. Aguilar, G. Bielicki, H. Becher, J. Castro, S. Iotti, M. G. Natali-Sora, E. Berta, S. Carlomagno, L. Ayuso-Peralta, P. H. Rondepierre, I. Bonaventura, B. V. Deuren, N. Van Blercom, M. Sciaky, J. Faber, M. Alberoni, M. Nieto, F. Sellal, C. Stelmasiak, M. Takao, J. Bradley, D. Zegers de Beyl, H. Porsche, G. Goi, H. Pongratz, F. Chapon, S. Happe, Robin S. Howard, B. Weder, S. Vlaski-Jekic, J. M. Ferro, R. Nemni, A. Daif, Herbert Budka, W. Van Paesschen, B. Waldecker, F. Carceller, J. Lacau, F. Soga, J. Peres Serra, E. Timmerman, A. M. vd Vliet, J. L. Emparanza, N. Vanacore, A. Pizzuti, N. Marti, A. Davalos, N. Ayraud, U. Zettl, J. Vivancos, Z. Katsarou, H. M. Mehdorn, G. Geraud, M. Merlini, M. Schröter, A. Ebner, M. Lanteri-Minet, R. Soler, G. P. Anzola, S. L. Hauser, L. Cahalon, S. DiDonato, R. Cantello, M. Marchau, J. Gioanni, F. Heidenreich, J. Manuel Martinez Lage, P. Descoins, F. Woimant, J. F. Campo, M. H. Verdier-taillefer, M. S. F. Barkhof, G. J. Kemp, A. O. Ceballos-Baumann, J. Berciano, M. Guidi, Tarek A. Yousry, B. Chandra, A. Rapoport, P. Canhao, A. Spitzer, T. Maeda, J. M. Pereira Monteiro, V. Paquis, Th. Mokrusch, F. J. Arrieta, I. Sangla, F. Canizares-Liebana, Lang Chr, André Delacourte, V. Fetoni, P. Kovachev, D. Kidd, L. Ferini-Strambi, E. Donati, E. Idman, A. Chio, C. Queiros, D. Michaelis, S. Boyacigil, A. Rodrigo, S. M. Yelamos, B. Chassande, P. Louwen, C. Tranchant, E. Ciafalon, A. Lombardo, A. Twijnstra, A. L. Fernandez, H. Kott, A. Cannas, N. Zsurger, T. Zileli, E. Metin, P. C. Bain, G. Fromont, B. Tedesi, A. Liberani, X. Navarro, M. C. Rowbotham, V. Hachinski, F. Cavalcanti, W. Rostene, R. M. Gardiner, F. Gonzalez, B. Köster, E. A. van der Veen, J. P. Lefaucheur, C. Marescaux, D. Boucquey, E. Parati, S. Yamaguchi, A. S. Orb, R. Grant, G. D. P. Smith, P. Goethals, M. Haguenau, G. Georgiev, I. N. van Schaik, Guy A. Rouleau, E. Iceman, G. Fayet, M. G. Kaplitt, C. Baracchini, H. Magnusson, G. Meneghetti, N. Malichard, M. L. Subira, D. Mancia, A. Berenguer, D. Navarrete Palau, H. Franssen, G. Kiziltan, M. P. Lopez, J. Montalt, S. Norby, R. Piedra Crespo, T. L. Rothstein, R. Falip, B. YalÇiner, F. Chedru, I. W. Thorpe, F. W. Heatley, D. S. C. Ochoa, C. Labaune, M. Devoti, O. Lider, Jakob Korf, N. Suzuki, E. A. Maguire, A. Moulignier, J. C. van Swieten, F. Monaco, J. Cartron, A. Steck, B. Uludag, M. Alexandra, H. Reichmann, T. Rossi, L. E. Claveria, A. M. Crouzel, M. A. Mena, J. Gasnault, J. W. Kowalski, S. I. Mellgren, V. Feigin, L. Demisch, J. Montalban, J. Renato, J. Mathieu, N. Goebels, L. Bava, K. Kunre, M. Pulik, S. Di Donato, C. Tzekov, H. Veldman, S. Giménez-Roldan, B. Lechevalier, L. Redondo, B. Pillon, M. Gugenheim, E. Roullet, J. M. Valdueza, C. Gori, H. J. Friedrich, L. de Saint Martin, F. Block, E. Basart, M. Heilmann, B. Becq Giraudon, C. Rodolico, G. Stevanin, Elizabeth K. Warrington, A. T. M. Willemsen, K. Kunze, C. Ben Hamida, M. Alam, J. R. ùther, A. Battistel, G. Della Marca, Richard S. J. Frackowiak, F. Palau, T. Brandt, Chicoutimi, L. Bove, L. Callea, A. Jaspert, T. Klopstock, K. Fassbender, Alan J. Thomas, A. Ferbert, V. Nunes, Douglas Russell, P. Garancini, C. Sanz-Sebastian, O. Santiag, G. Dhaenens, G. Seidel, I. Savic, A. Florea-Strat, M. Rousseaux, N. Catala, E. O'Sullivan, M. J. Manifacier, H. Kurtel, T. Mendel, P. Chariot, M. Salas, D. Brenton, R. Lopez, J. Thorpe, Jimmy D. Bell, E. Hofmann, E. Botia, J. Pacquereau, A. Struppler, C. d'Aniello, D. Conway, A. Garcia-Merino, K. Toyooka, S. Hodgkinson, E. Ciusani, Stefano Bastianello, A. Andrade Filho, M. Zaffaroni, G. Pleiffer, F. Coria, A. Schwartz, D. Baltadjiev, I. Rother, K. Joussen, J. Touchon, K. Kutlul, P. Praamstra, H. Sirin, S. Richard, C. Mariottu, L. Frattola, S. T. Dekesky, G. Wieneke, M. Chatel, O. Godefroy, C. Desnuelle, S. OzckmekÇi, C. H. Zielinski, P. van Deventer, S. Jozwiak, I. Galan, J. M. Grau, V. Vieira, T. A. Treves, S. Ertan, A. Pujol, S. Blecic, E. M. Zanette, F. Ceriani, W. Camu, L. Aquilone, A. Benomar, F. Greco, A. Pascual-Leone Pascual, T. Yanagihara, F. A. Delfino, R. Damels, S. Merkelbach, J. Beltran, A. Barrientos, S. Brugge, B. Hildebrandt-Müller, M. H. Nascimento, M. Rocchi, F. Cervantes, E. Castelli, R. M. Pressler, S. Yeil, A. del Olmo, J. L. Herranz, L. J. Kappelle, Y. Demir, N. Inoue, R. Hershkoviz, A. Luengo, S. Bien, F. Viallet, P. Malaspina, G. De Michele, G. Nolfe, P. Adeleine, T. Liehr, G. Fenelon, H. Masson, Kailash P. Bhatia, W. Haberbosch, S. Mederer, R. S. J. Frackowiak, Tanya Stojkovic, S. Previtali, A. E. Harding, W. Kohler, N. P. Quin, T. R. Marra, J. P. Moisan, A. Melchor, M. L. Viguera, Mary G. Sweeney, G. L. Romani, J. Hezel, R. A. Dierckx, R. Torta, A. Kratzer, T. Pauwels, D. Decoo, Adriana Campi, Neil Kitchen, J. Haas, U. Neubauer, J. J. Merland, A. Yagiz, A. Antonuzzo, A. Zangaladze, J. Parra, Pablo Martinez-Lage, D. J. Brooks, S. Hauser, R. Di Pierri, M. Campero, R. Caldarelli-Stefano, A. M. Colangelo, J. L. Pozo, C. Estol, F. Picard, A. Palmieri, J. Massons, JT Phillips, G. B. Groozman, R. Pentore, L. M. Ossege, C. Bayon, Hans-Peter Hartung, R. Konyalioglu, R. Lampis, D. Ancri, M. Miletta, F. J. Claramonte, W. Retz, F. Hentges, JM Cooper, M. Cordes, M. Limburg, M. Brock, G. R. Coulton, K. Helmke, Rosa Larumbe, A. Ohly, F. Landgraf, A. M. Drewes, Claudia Trenkwalder, M. Keidel, T. Segura, C. Scholz, J. HÄgele, D. Baudoin-Martin, P. Manganelli, J. Valdueza, M. Farinotti, U. Zwiener, M. P. Schiavalla, Y. P. Young, O. Barlas, G. Hertel, E. H. Weiss, M. Eiselt, A. Lossos, M. Bartoli, L. Krolicki, W. Villafana, W. Peterson, Nicoletta Meucci, C. Agbo, R. Luksch, F. Fiacco, G. Ponsot, M. Lopez, Howard L. Weiner, M. D. Alonso, K. Petry, Sanjay M. Sisodiya, P. Giustini, S. Tyrdal, R. Poupon, J. Blanke, P. Oubary, A. A. Kruize, H. Trabucchi, R. R. C. Stewart, H. Grehl, B. M. Kulig, V. Vinhas, D. Spagnoli, B. Mahe, J. Tatay, C. Hess, M. D. Albadalejo, G. Birbamer, M. Alonso, F. Valldeoriola, J. Figols, I. Wirguin, E. Diez Tejedor, C. S. Weiller, L.H. van den Berg, P. Barreiro, L. Pianese, S. Cocozza, R. Kohnen, E. Redolfi, F. Faralli, G. Gosztonyl, A. J. Gur, A. Keyser, V. Fichter-Gagnepain, B. Wildemann, E. Omodeo-Zorini, Gregoire, J. Schopohl, F. Fraschini, G. Wunderlich, B. Jakubowska, F. P. Serra, N. B. Jensen, O. Delattre, C. Leno, A. Dario, P. Grafe, F. Graus, M. C. Vigliani, J. L. Dobato, Philip N. Hawkins, R. Marés, A. Rimola, N. Meussi, G. Aimard, W. Hospers, A. M. Robertson, C. Kaplan, W. Lamadé, Karen E. Morrison, Amadio, E. Kieffer, F. Dromer, P. Bernasconi, M. Repeto, Davide Pareyson, Jeremy Rees, A. Guarneri, P. Odin, P. Bouche, L. Nogueira, J. Munoz, L. Leocani, M. J. Arcusa, R. S. J. Frackowiack, John S. Duncan, D. Karacostas, D. Edwin, I. Costa, M. Menetrey, P. Grieb, A. M. Salvan, S. Cunha, P. Merel, P. Pfeiffer, A. Astier, F. Federico, A. Mrabet, M. G. Buzzi, L. Knudsen, I. F. Pye, L. Falqui, C. R. Hornig, C. E. Shaw, C. Brigel, T. C. Britton, R. Codoceo, T. Pampols, Vincent J. Cunningham, N. Archidiacono, G. Chazot, J. B. Posner, L. L. O. Befalo, M. Monclus, C. Cabezas, H. Moser, H. Stodal, J. Ley-Pozo, L. Brusa, R. Di Mascio, P. Giannini, J. Fernandez, R. Santiago Luis, J. Garcia Tigera, J. Wilmink, P. Pignatelli, M. El Amrani, V. Lucivero, M. Baiget, R. Lodi, P. H. Cabre, L. Grande, A. Korczyn, R. Fahlbusch, C. Milanese, W. Huber, J. Susseve, H. C. Nahser, K. Mondrup, X. O. Breakefield, J. Sarria, T. H. Vogt, A. Alessandri, M. Daffertshofer, I. Nelson, M. L. Monticelli, O. Dammann, G. G. Farnarier, G. Felisari, A. Quattrini, A. Boiardi, P. Mazetti, H. Liu, J. Duarte, M. E. Gaunt, H. Strik, N. Yulug, A. Urman, J. Posner, Aida Suarez Gonzalez, Ma. L. Giros, Z. Matkovic, D. Kompf, A. D. Korczyn, A. Steinbrecher, R. Wenzel, M. C. de Rijk, R. Doronzo, J. Julien, O. Hasegawa, M. Kramer, V. Collado-Scidel, M. Alonso de Lecinana, L. Dell'Arciprete, S. Rapuzzi, S. Bahar, H. Willison, M. T. Ramacci, J.J. Martin, Lopez-Bresnahan, C. Malapani, R. Haaxma, T. Rosenberg, J. Patrignani, R. Vichi, Martin R. Farlow, J. Roquer, L. Krols, M. Pimenta, C. Bucka, U. Klose, M. Roberts, J. Salas-Puig, R. Ghnassia, A. Mercuri, C. Maltempo, I. Tournev, P. Homeyer, D. Caparros-Lefevre, E. P. O. Sullivan, T. Vashadze, Ph. Lyrer, A. Deltoro, H. Kondo, M. Steinling, A. Graham, G. C. Miescher, A. Pace, D. Branca, G. Avello, H. H. Kornhuber, D. Fernandes, H. Friedrich, R. Chorao, H. O. Lüders, R. T. Bax, J. A. Macias, N. Yilmaz, J. Veroust, M. Miller, S. Confort-Gouny, J. L. Sastre, D. Servello, G. Boysen, S. Koeppen, V. Planté-Bordeneuve, H. Albrecht, R. H. M. King, G. Orkodashili, R. Doornbos, H. Toyooka, V. Larrue, M. Sabatelli, K. Williams, M. Stevens, V. Maria, M. Comabella, C. Lammers, R. M. L. Poublon, E. Tizzano, P. Pazzaglia, F. Zoeller, M. B. Delisle, J. P. Goument, J. M. Minderhoud, A. Sghirlanzoni, V. Meininger, M. Al Deeb, C. Bertelt, A. Cagni, A. Algra, F. Morales, K. A. Flugel, M. Maidani, M. Noya, Z. Seidl, U. Roelcke, D. Cannata, E. Katiane EmbiruÇu, E. M. Wicklein, K. Willmes, L. Hanoglu, J. F. Pellissier, Yves Agid, E. Cuadrado, S. Brock, D. Maimone, Z. G. Nadareishvili, E. Matta, S. Hilmi, V. Assuerus, F. Lomena, R. Springer, F. Cabrera-Valdivia, Oscar L. Lopez, M. Casazza, F. Vivancos, Ralf Gold, T. Crawford, B. Moulard, M. Poisson, W. l. McDonald, D. E. Grobbe, Alan Connelly, H. Ozcan, S. Abeta, H. Severo Ochoa, A. C. van Loenen, E. Libson, M. J. Marti, B. George, C. Ferrarese, B. Jacobs, L. Divano, T. Ben-Hur, A. L. Bootsma, V. Martinez, A. Conti, R. P. Maguire, B. Schmidt, D. M. Campos, D. A. Guzman, E. Meary, C. Richart, P. B. Christensen, T. Schroeder, Massimo Zeviani, K. Jensen, R. Aliaga, S. Seitz-Dertinger, J. W. Griffin, C. Fryze, H. Baas, S. Braun, A. M. Porrini, B. Yemez, M. J. Sedano, C. Creisson, A. Del Santo, A. Mainz, R. Kay, S. Livraghi, R. de Waal, D. Macgregor, H. Hefter, R. Garghentino, U. Ruotsalainen, M. Matsumoto, M. G. Beaudry, P. M. Morrison, J. C. Petit, C. Walon, Ph. Chemouilli, F. Henderson, R. Massa, A. Cruz Martinez, U. Liska, F. Hecht, Ernst Holler, V. S. de Bruin, B. B. Sheitman, S. M. Bentzen, C. Bayindir, F. Pallesta, P. E. Roland, J. Parrilla, P. Zunker, L. F. Burchinskaya, G. Mellino, S. Ben Ayed, D. Bonneau, P. Nowacki, M. Goncalves, P. Riederer, N. Mavroudakis, J. Togores, L. Rozewicz, S. Robeck, Y. Perez Gilabert, L. Rampello, A. Rogopoulos, S. Martinez, F. Schildermans, C. Radder, P. B. Hedlund, J. Cambier, M. Aabed, G. D. Jackson, P. Gasparini, P. Santacruz, J. Vandevivere, H. Dural, A. Mantel, W. Dorndorf, N. Ediboglu, A. Lofgren, J. Bogousslavsky, P. Thierauf, L. Goullard, R. Maserati, B. Moering, M. Ryba, J. Serra, G. G. Govan, A. Pascual-Leone, S. Schaeffer, M. R. Rosenfeld, A. P. Correia, K. Ray Chaudhuri, L. Campbell, R. Spreafico, B. Genetet, A. M. Tantot, R. A. G. Hughes, J. A. Vidal, G. Erkol, J. Y. Delattre, B. Yaqub, B. K. Hecht, E. Mayayo, Ph. Scheltens, J. Corral, M. Calaf, L. Henderson, C. Y. Li, U. Bogdahn, R. Sanchez-Roy, M. Navasa, J. Ballabriga, G. Broggi, T. Gudeva, C. Rose, J. Vion-Dury, J. A. Gastaut, J. Pniewski, Nicola J. Robertson, G. Kohncke, M. Billot, S. Gok, E. Castellli, F. Denktas, P. Bazzi, F. Spinelli, I. F. Moseley, C. D. Mardsen, B. Barbiroli, O. M. Koriech, A. Miller, Hiroaki Yoshikawa, F. X. Borruat, J. Zielasek, P. Le Coz, J. Pascual, A. Drouet, L. T. Giron, F. Schondube, R. Midgard, M. Alizadeh, M. Liguori, Lionel Ginsberg, L. Harms, C. Tilgner, G. Tognoni, F. Molteni, Mar Tintoré, M. Psylla, C. Goulon-Goeau, M. V. Aguilar, Massimo Filippi, K. H. Mauritz, Thomas V. Fernandez, C. Basset, S. Rossi, P. Meneses, B. Jandolo, T. Locatelli, D. Shechtcr, C. Magnani, R. Ferri, Bruno Dubois, J. M. Warier, S. Berges, F. Idiman, M. Schabet, R. R. Diehl, P. D'aurelio, M. Musior, Reinhard Hohlfeld, P. Smeyers, M. Olivé, A. Riva, C. A. Broere, N. Egund, S. Franceschetti, V. Bonavita, Nicola Canal, E. Timmermans, M. Ruiz, S. Barrandon, G. Vasilaski, B. Deweer, L. Galiano, S. F. T. M. de Bruijn, L. Masana, A. Goossens, B. Heye, K. Lauer, Heinz Gregor Wieser, Stephen R. Williams, B. Garavaglia, A. P. Sempere, F. Grigoletto, P. Poindron, R. Lopez-Pajares, I. Leite, T. A. McNell, C. Caucheteur, J. M. Giron, A. D. Collins, P. Freger, J. Sanhez Del Rio, D. A. Harn, K. Lindner, S. S. Scherer, G. Serve, M. Juncadella, X. Estivill, R. Binkhorst, M. Anderson, B. Tekinsoy, C. Sagan, T. Anastopoulos, G. Japaridze, S. Guillou, F. Erminio, Jon Sussman, P. G. Oomes, D. S. Rust, S. Mascheroni, O. Berger, M. Peresson, K. V. Toyka, T. W. Polder, M. Huberman, B. Arpaci, H. Ramtami, I. Martinez, Ph. Violon, P. P. Gazzaniga Pozzill, R. Ruda, P. Auzou, J. Parker, S. P. Morrissey, Jiahong Zhu, F. Rotondi, P. Baron, W. Schmid, P. Doneda, M. Spadaro, M. C. Nargeot, I. Banchs, J.S.P. van den Berg, R. Ferrai, M. Robotti, M. Fredj, Pedro M. Rodríguez Cruz, B. Erne, D. G. Piepgras, M. C. Arne-Bes, J. Escudero, C. Goetz, A. R. Naylor, M. Hallett, O. Abramsky, E. Bonifacio, L. E. Larsson, R. Pellikka, P. Valalentino, D. Guidetti, B. Buchwald, C. H. Lücking, D. Gauvreau, F. Pfaff, A. Ben Younes-Chennoufi, R. Kiefer, R. Massot, K. A. Hossmann, L. Werdelin, P. J. Baxter, U. Ziflo, S. Allaria, C. D. Marsden, M. Cabaret, S. P. Mueller, E. Calabrese, R. Colao, S. I. Bekkelund, M. Yilmaz, O. Oktem-Tanor, R. Gine, M. E. Scheulen, J. Beuuer, A. Melo, Z. Gulay, M. D. Have, C. Frith, D. Liberati, J. Gozlan, P. Rondot, Ch. Brunholzl, M. Pocchiari, J. Pena, L. Moiola, C. Salvadori, A. Cabello, T. Catarci, S. Webb, C. Dettmers, N. A. Gregson, Alexandra Durr, F. Iglesias, U. Knorr, L. Ferrini-Strambi, F. Kruggel, P. Allard, A. Coquerel, P. Genet, F. Vinuels, C. Oberwittler, A. Torbicki, P. Leffers, B. Renault, B. Fauser, C. Ciano, G. Uziel, J. M. Gibson, F. Anaya, C. Derouesné, C. N. Anagnostou, M. Kaido, W. Eickhoff, G. Talerico, M. L. Berthier, A. Capdevila, M. Alons, D. Rezek, E. Wondrusch, U. Kauerz, D. Mateo, M. A. Chornet, Holon, N. Pinsard, I. Doganer, E. Paoino, H. Strenge, C. Diaz, J. R. Brasic, W. Heide, I. Santilli, W. M. Korn, D. Selcuki, M. J. Barrett, D. Krieger, T. Leon, T. Houallah, M. Tournilhac, C. Nos, D. Chavot, F. Barbieri, F. J. Jimenez-Jimenez, J. Muruzabal, K. Poeck, A. Sennlaub, L. M. Iriarte, L. G. Lazzarino, C. Sanz, P. A. Fischer, S. D. Shorvon, R. Hoermann, F. Delecluse, M. Krams, O. Corabianu, F. H. Hochberg, Christopher J. Mathias, B. Debachy, C. M. Poser, L. Delodovici, A. Jimenez-Escrig, F. Baruzzi, F. Godenberg, D. Cucinotta, P. J. Garcia Ruiz, K. Maier-Hauff, P. R. Bar, R. Mezt, R. Jochens, S. Karakaneva, C. Roberti, E. Caballero, Joseph E. Parisi, M. Zamboni, T. Lacasa, B. Baklan, J. C. Gautier, J. A. Martinez-Matos, W. Pollmann, G. Thomas, L. Verze, E. Chleide, R. Alvarez Sala, I. Noel, E. Albuisson, O. Kastrup, S. I. Rapoport, H. J. Braune, H. Lörler, M. Le Merrer, A. Biraben, S. Soler, S. J. Taagholt, U. Meyding-Lamadé, K. Bleasdale-Barr, Isabella Moroni, Y. Campos, J. Matias-Guiu, G. Edan, M. G. Bousser, John B. Clark, J. Garcia de Yebenes, N. K. Olsen, P. Hitzenberger, S. Einius, Aj Thompson, Ch. J. Vecht, T. Crepin-Leblond, Klaus L. Leenders, A. Di Muzio, L. Georgieva, René Spiegel, K. Sabey, D. Ménégalli, J. Meulstee, U. Liszka, P. Giral, C. Sunol, J. M. Espadaler, A. D. Crockar, K. Varli, G. Giraud, P. J. Hülser, A. Benazzouz, A. Reggio, M. Salvatore, K. Genc, M. Kushnir, S. Barbieri, J. Ph. Azulay, M. Gianelli, N. Bathien, A. AlMemar, F. Hentati, I. Ragueneau, F. Chiarotti, R. C. F. Smits, A. K. Asbury, F. Lacruz, B. Muller, Alan J. Thompson, Gordon Smith, K. Schmidt, C. Daems Monpeun, Juergen Weber, A. Arboix, G. R. Fink, A. M. Cobo, M. Ait Kaci Ahmed, E. Gencheva, Israel-Biet, G. Schlaug, P. De Jonghe, Philip Scheltens, K. Toyka, P. Gonzalez-Porque, A. Cila, J. M. Fernandez, P. Augustin, J. Siclia, S. Medaglini, D. E. Ziogas, A. Feve, L. Kater, G. J. E. Rinkel, D. Leppert, Rüdiger J. Seitz, S. Ried, C. Turc-Carel, G. Smeyers, F. Godinho, M. Czygan, M. Rijntjes, E. Aversa, M. Frigo, Leif Østergaard, J. L. Munoz Blanco, A. Cruz-Matinez, J. De Reuck, C. Theillet, T. Barroso, V. Oikonen, Florence Lebert, M. Kilinc, C. Cordon-Cardon, G. Stoll, E. Thiery, F. Pulcinelli, J. Solski, M. Schmiegelow, L. J. Polman, P. Fernandez-Calle, C. Wikkelso, M. Ben Hamida, M. Laska, E. Kott, W. Sulkowski, C. Lucas, N. M. Bornstein, D. Schmitz, M. W. Lammers, A. de Louw, R. J. S. Wise, P. A. van Darn, C. Antozzi, P. Villanueva, P. H. E. Hilkens, C. Constantin, W. Ricart, A. Wolf, M. Gamba, P. Maguire, Alessandro Padovani, B. M. Patten, Marie Sarazin, H. Ackermann, L. Durelli, S. Timsit, Sebastian Jander, B. W. Scheithauer, G. Demir, J. P. Neau, P. Barbanti, A. Brand, N. AraÇ, V. Fischer-Gagnepain, R. Marchioli, G. Serratrice, C. Maugard-Louboutin, G. T. Spencer, D. Lücke, G. Mainardi, K. Harmant Van Rijckevorsel, G. B. Creel, R. Manzanares, Francesco Fortunato, A. May, J. Workman, K. Johkura, E. Fernandez, Carlo Colosimo, L. Calliauw, L. Bet, Félix F. Cruz-Sánchez, M. Dhib, H. Meinardi, F. Carrara, J. Kuehnen, C. Peiro, H. Lassmann, K. Skovgaard Olsen, A. McDonald, L. Sciulli, A. Cobo, A. Monticelli, B. Conrad, J. Bagunya, J. Benitez, V. Desnizza, B. Dupont, O. Delrieu, D. Moraes, J. J. Heimans, F. Garcia Rio, M. Matsumto, A. Fernandez, R. Nermni, R. Chalmers, M. J. Marchau, F. Aguado, P. Velupillai, P. J. Martin, P. Tassan, V. Demarin, A. Engelien, T. Gerriets, Comar, J. L. Carrasco, J. P. Pruvo, A. Lopez de Munain, D. Pavitt, J. Alarcon, Chris H. Polman, B. Guldin, N. Yeni, Hartmut Brückmann, N. Wilczak, H. Szwed, R. Causaran, G. Kyriazis, M. E. Westarp, M. Gasparini, N. Pecora, J. M. Roda, E. Lang, V. Scaioli, David R. Fish, D. Caputo, O. Gratzl, R. Mercelis, A. Perretti, G. Steimetz, I. Link, C. Rigoletto, A. Catafau, G. Lucotte, M. Buti, G. Fagiolari, A. Piqueras, C. Godinot, J. C. Meurice, Erodriguez J. Dominigo, F. Lionnet, H. Grzelec, David J. Brooks, P. M. G. Munro, F. X. Weilbach, M. Maiwald, W. Split, B. Widjaja-Cramer, V. Ozturk, J. Colas, E. Brizioli, J. Calleja, L. Publio, M. Desi, R. Soffietti, P. Cortinovis-Tourniaire, E. F. Gonano, G. Cavaletti, S. Uselli, K. Westerlind, H. Betuel, C. O. Dhiver, H. Guggenheim, M. Hamon, R. Fazio, P. Lehikoinen, A. Esser, B. Sadzot, G. Fink, Angelo Antonini, D. Bendahan, V. Di Carlo, G. Galardi, A. F. Boller, M. Aksenova, Del Fiore, V. de la Sayette, H. Chabriat, A. Nicoletti, A. Dilouya, M. L. Harpin, E. Rouillet, J. Stam, A. Wolters, M. R. Delgado, Eduardo Tolosa, G. Said, A. J. Lees, L. Rinaldi, A. Schulze-Bonhage, MA Ron, C. Lefebvre, E. W. Radü, R. Alvarez, M. L. Bots, P. Reganati, S. Palazzi, A. Poggi, N. J. Scolding, V. Sazdovitch, T. Moreau, E. Maes, M. A. Estelies, P. Petkova, Jose-Felix Marti-Masso, G De La Meilleure, N. Mullatti, M. Rodegher, N. C. Notermans, T. A. T. Warner, S. Aktan, J. P. Louboutin, L. Volpe, C. Scheidt, W. Aust, C. M. Wiles, U. Schneider, S. K. Braekken, W. R. Willems, K. Usuku, Peter M. Rothwell, C. Talamon, M. L. Sacchetti, A. Codina, M. H. Marion, A. Santoro, J. Roda, A. Bordoni, D. J. Taylor, S. Ertas, H. H. Emmen, J. Vichez, V. BesanÇon, R. E. Passingham, M. L. Malosio, A. Vérier, M. Bamberg, A. W. Hansen, E. Mostacero, G. Gaudriault, Marie Vidailhet, B. Birebent, K. Strijckmans, F. Giannini, T. Kammer, I. Araujo, J. Nowicki, E. Nikolov, A. Hutzelmann, R. Gherardi, J. Verroust, L. Austoni, A. Scheller, A. Vazquez, S. Matheron, H. Holthausen, J. M. Gerard, M. Bataillard, S. Dethy, V. H. Patterson, V. Ivanez, N. P. Hirsch, F. Ozer, M. Sutter, C. Jacomet, M. Mora, Bruno Colombo, A. Sarropoulos, T. H. Papapetropoulos, M. Schwarz, D. S. Dinner, N. Acarin, B. Iandolo, J. O. Riis, P. R. J. Barnes, F. Taroni, J. Kazenwadel, L. Torre, A. Lugaresi, I. L. Henriques, S. Pauli, S. Alfonso, Pedro Quesada, A. S. T. Planting, J. M. Castilla, Thomas Gasser, M. Van der Linden, A. Alfaro, E. Nobile-Orazio, G. Popova, W. Vaalburg, F. G. A. van der Mech, L. Williams, F. Medina, J. P. Vernant, J. Yaouanq, B. Storch-Hagenlocher, A. Potemkowski, R. Riva, M. H. Mahagne, M. Ozturk, Ve. Drory, N. Konic, C. Jungreis, A. Pou Serradell, J. L. Gauvrit, G. J. Chelune, S. Hermandez, T. Dingus, L. Hewer, Ch. Koch, M. N. Metz-Lutz, G. Parlato, M. Sinaki, Charles Pierrot-Deseilligny, H. C. Diener, J. Broeckx, J. Weill-Fulazza, M. L. Villar, M. Rizzo, O. Ganslandt, C. Duran, N. A. Fletcher, G. Di Giovacchino, Susan T. Iannaccone, C. Kolig, N. Fabre, H. A. Crockard, Rita Bella, M. Tazir, E. Papagiannuli, K. Overgaard, Emma Ciafaloni, I. Lorenzetti, F. Viader, P. A. H. Millac, I. Montiel, L. H. Visser, M. Palomar, P. L. Murgia, H. Pedersen, Rafael Blesa, S. Seddigh, W. O. Renier, I. Lemahieu, H. M. L. Jansen, L. Rosin, J. Galofre, K. Mattos, M. Pondal, G. M. Hadjigeorgiou, D. Francis, L. Cantin, D. Stegeman, M. Rango, A. B. M. F. Karim, S. Schraff, B. Castellotti, I. Iriarte, E. Laborde, T. J. Tjan, R. Mutani, D. Toni, B. Bergaasco, J. G. Young, C. Klotzsch, A. Zincone, X. Ducrocq, M. Uchuya, O. J. Kolar, A. Quattrone, T. Bauermann, Nereo Bresolin, J. Vallée, B. C. Jacobs, A. Campos, Werner Poewe, J. A. Villanueva, A. W. Kornhuber, A. Malafosse, E. Diez-Tejedor, G. Jungreia, M. J. A. Puchner, A. Komiyama, O. Saribas, V. Volpini, L. Geremia, S. Bressi, A. Nibbio, Timothy E. Bates, T. z. Tzonev, E. Ideman, G. A. Damlacik, G. Martino, G. Crepaldi, T. Martino, Kjell Någren, E. Idiman, D. Samuel, J. M. Perez Trullen, Y. van der Graaf, J. O. Thorell, M. J. M. Dupuis, E. Sieber, R. D'Alessandro, C. Cazzaniga, J. Faiss, A. Tanguy, A. Schick, I. Hoksergen, A. Cardozo, R. Shakarishvili, G. K. Wennlng, J. L. Marti-Vilalta, J. Weissenbach, I. L. Simone, Amalia C. Bruni, Darius J. Adams, C. Weiller, A. Pietrangeli, F. Croria, C. Vigo-Pelfrey, Patricia Limousin, A. Ducros, G. Conti, O. Lindvall, E. Richter, M. Zuffi, A. Nappo, T. Riise, J. Wijdenes, M. J. Fernandez, J. Rosell, P. Vermersh, S. Servidei, M. S. C. Verdugo, F. Gouttiere, W. Solbach, M. Malbezin, I. S. Watanabe, A. Tumac, W. I. McDonald, D. A. Butterfield, P. P. Costa, F. deRino, F. Bamonti, J. M. Cesar, C. H. Lahoz, I. Mosely, M. Starck, M. H. Lemaitre, K. M. Stephan, S. Tex, R. Bokonjic, I. Mollee, L. Pastena, M. Gutierrez, F. Boiler, M. C. Martinez-Para, M. Velicogna, O. Obuz, A. Grinspan, M. Guarino, L. M. Cartier, E. Ruiz, D. Gambi, S. Messina, M. Villa, Michael G. Hanna, J. Valk, Leone Pascual, M. Clanet, Z. Argov, B. Ryniewicz, E. Magni, B. Berlanga, K. S. Wong, C. Gellera, C. Prevost, F. Gonzalez-Huix, R. Petraroli, J. E. G. Benedikz, I. Kojder, C. Bommelaer, L. Perusse, M. R. Bangioanni, Guy M. McKhann, A. Molina, C. Fresquet, E. Sindern, Florence Pasquier, M. J. Rosas, M. Altieri, O. Simoncini, M. Koutroumanidis, C. A. F. Tulleken, M. Dary-Auriol, S. Oueslati, H. Kruyer, I. Nishisho, C. R. Horning, A. Vital, G. V. Czettritz, J. Ph. Neau, B. Mihout, A. Ameri, M. Francis, S. Quasthoff, D. Taussig, S. Blunt, P. Valentin, C. Y. Gao, O. Heinzlef, H. d'Allens, C. Coudero, M. Erfas, G. Borghero, P. J. Modrego Pardo, M. C. Patrosso, N. L. Gershfeld, P. A. J. M. Boon, O. Sabouraud, M. Lara, J. Svennevig, G. L. Lenzi, A. Barrio, H. Villaroya, JosÇ M. Manubens, O. Boespflug-Tanguy, M. Carreras, D. A. Costiga, J. P. Breux, S. Lynn, C. Oliveras Ley, A. G. Herbaut, J. Nos, C. Tornali, Y. A. Hekster, J. L. Chopard, J. M. Manubens, P. Chemouilli, A. Jovicic, F. Dworzak, S. Smirne, S. E. Soudain, B. Gallano, D. Lubach, G. Masullo, G. Izquierdo, A. Pascual Leone Pascual, A. Sessa, V. Freitas, O. Crambes, L. Ouss, G. W. Van Dijk, P. Marchettini, P. Confalonieri, M. Donaghy, A. Munnich, M. Corbo, and M. E. L. van der Burg
- Subjects
Neurology ,business.industry ,Media studies ,Library science ,Medicine ,Neurology (clinical) ,business - Published
- 1994
- Full Text
- View/download PDF
13. Abstracts
- Author
-
J. M. Derlon, M. C. Petit-taboué, F. Dauphin, P. Courtheoux, F. Chapon, P. Creissard, F. Darcel, J. P. Houtteville, B. Kaschten, B. Sadzot, A. Stevenaert, Juri G. Tjuvajev, Homer A. Macapinlac, Farhad Daghighian, James Z. Ginos, Ronald D. Finn, M. S. Jiaju Zhang, Bradley Beattie, Martin Graham, Steven M. Larson, Ronald G. Blasberg, M. Levivier, S. Goldman, B. Pirotte, J. M. Brucher, D. Balériaux, A. Luxen, J. Hildebrand, J. Brotchi, K. G. Go, R. L. Kamman, E. L. Mooyaart, M. A. A. M. Heesters, P. E. Sijens, M. Oudksrk, P. van Dijk, P. C. Levendag, Ch. J. Vecht, R. J. Metz, D. N. Kennedy, B. R. Rosen, F. H. Hochberg, A. J. Fishman, P. A. Filipek, V. S. Caviness, M. W. Gross, F. X. Weinzierl, A. E. Trappe, W. E. Goebel, A. M. Frank, Georg Becker, Andreas Krone, Karsten Schmidt, Erich Hofmann, Ulrich Bogdahn, H. Bencsch, S. Fclber, G. Finkenstedt, C. Kremser, G. Sfockhammer, F. Aichner, U. Bogdahn, T. Fröhlich, G. Becker, A. Krone, R. Schlief, J. Schürmann, P. Jachimczak, E. Hofmann, W. Roggendorf, K. Roosen, C. M. Carapella, G. Carpinelli, R. Passalacqua, L. Raus, M. Giannini, R. Mastrostefano, F. Podo, A. Tofani, R. Maslrostefano, M. Mottoles, A. Ferraironi, M. G. Scelsa, P. Oppido, A. Riccio, C. L. Maini, L. Collombier, L. Taillandier, M. Dcbouverie, M. H. Laurens, P. Thouvenot, M. Weber, A. Bertrand, G. S. Cruickshank, J. Patterson, D. Hadley, Olivier De Witte, Jerzy Hildebrand, André Luxen, Serge Goldman, R. -I. Ernestus, K. Bockhorst, M. Eis, T. Els, M. Hoehn-Berlage, M. Gliese, R. Fründ, A. Geissler, C. Woertgen, M. Holzschuh, O. Hausmann, A. Merlo, E. Jerrnann, J. Uirich, R. Chiquet-Ehrismann, J. Müller, H. Mäcke, O. Gratzl, K. Herholz, M. Ghaemi, M. Würker, U. Pietrzyk, W. -D. Heiss, K. Kotitschke, M. Brandl, J. C. Tonn, A. Haase, S. Muigg, S. Felber, M. Woydt, Heinrich Lanfermann, Walter Heindel, Harald Kugel, Ralf -Ingo Erneslus, Gabricle Röhn, Klaus Lackner, F. S. Pardo, S. Kutke, A. G. Sorensen, L. L. Mechtler, S. Withiam-Lench, K. Shin, W. R. Klnkel, M. Patel, B. Truax, P. Kinkel, L. Mechtler, M. Ricci, P. Pantano, A. Maleci, S. Pierallini, D. Di Stefano, L. Bozzao, G. P. Cantore, Gabriele Röhn, R. Schröder, R. Ruda, C. Mocellini, R. Soffietti, M. Campana, R. Ropolo, A. Riva, P. G. de Filippi, D. Schiffer, D. Salgado, M. Rodrigues, L. Salgado, A. T. Fonseca, M. R. Vieira, J. M. Bravo Marques, H. Satoh, T. Uozumi, K. Kiya, K. Kurisu, K. Arita, M. Sumida, F. Ikawa, Tz. Tzuk-Shina, J. M. Gomori, R. Rubinstein, A. Lossos, T. Siegal, W. Vaalburg, A. M. J. Paans, A. T. M. Willemsen, A. van Waarde, J. Pruim, G. M. Visser, S. Valentini, Y. L. T. Ting, R. De Rose, G. Chidichimo, G. Corricro, Karin van Lcycn-Pilgram, Ralf -Ingo Erncslus, Norfried Klug, K. van Leyen-Pilgram, N. Klug, U. Neumann, Karl H. Plate, Georg Breier, Birgit Millaucr, Herbert A. Weich, Axel Ullrich, Werner Risau, N. Roosen, R. K. Chopra, T. Mikkelsen, S. D. Rosenblum, P. S. Yan, R. Knight, J. Windham, M. L. Rosenblum, A. Attanasio, P. Cavalla, A. Chio, M. T. Giordana, A. Migheli, V. Amberger, T. Hensel, M. E. Schwab, Luigi Cervoni, Paolo Celli, Roberto Tarantino, C. Huettner, U. Berweiler, I. Salmon, S. Rorive, K. Rombaut, J. Haot, R. Kiss, C. Maugard-Louboutin, J. Charrier, G. Fayet, C. Sagan, P. Cuillioere, G. Ricolleau, S. Martin, D. Menegalli-Bogeelli, Y. Lajat, F. Resche, Péter Molnàr, Helga Bárdos, Róza Ádány, J. P. Rogers, G. J. Pilkington, B. Pollo, G. Giaccone, A. Allegranza, O. Bugiani, J. Prim, J. Badia, E. Ribas, F. Coello, E. Shezen, O. Abramsky, M. Scerrati, R. Roselli, M. Iacoangeli, A. Pompucci, G. F. Rossi, Saleh M. Al. Deeb, Osama Koreich, Basim Yaqub, Khalaf R. Al. Moutaery, S. Marino, M. C. Vigliani, V. Deburghgraeve, D. Gedouin, M. Ben Hassel, Y. Guegan, B. Jeremic, D. Grujicic, V. Antunovic, M. Matovic, Y. Shibamoto, Merja Kallio, Helena Huhmar, Ch. Kudoh, A. Detta, K. Sugiura, E. R. Hitchcock, R. Di Russo, M. Cipriani§, E. M. Occhipinti, E. M. S. Conti, A. Clowegeser, M. Ortler, M. Seiwald, H. Kostron, B. Rajan, G. Ross, C. Lim, S. Ashlcy, D. Goode, D. Traish, M. Brada, G. A. C. vd Sanden, L. J. Schouten, J. W. W. Coebergh, P. P. A. Razenberg, A. Twijnstra, A. Snilders-Keilholz, J. H. C. Voormolen, J. Hermans, J. W. H. Leer, F. Baylac, M. Dcbouvcrie, R. Anxionnal, S. Bracard, J. M. Vignand, A. Duprcz, M. Winking, D. K. Böker, T. Simmet, David Rothbart, John Strugar, Jeroen Balledux, Gregory R. Criscuolo, Piotr Jachimczak, Armin Blesch, Birgit Heβdörfer, Ralf -Ingo Ernestus, Roland Schröder, Norfrid Klug, H. G. J. Krouwer, S. G. v. Duinen, A. Algra, J. Zentner, H. K. Wolf, B. Ostertun, A. Hufnagel, M. G. Campos, L. Solymosi, J. Schramm, E. S. Newlands, S. M. O'Reilly, M. Brampton, R. Sciolla, D. Seliak, R. Henriksson, A. T. Bergenheim, P. Björk, P. -O. Gunnarsson, Ml. Hariz, R. Grant, D. Collie, A. Gregor, K. P. Ebmeier, G. Jarvis, F. Lander, A. Cull, R. Sellar, C. Thomas, S. Elyan, F. Hines, S. Ashley, S. Stenning, J. J. Bernstein, W. J. Goldberg, U. Roelcke, K. Von Ammon, E. W. Radu, D. Kaech, K. L. Leenders, M. M. Fitzek, J. Efird Aronen, F. Hochberg, M. Gruber, E. Schmidt, B. Rosen, A. Flschman, P. Pardo, U. M. U. Afra, L. Sipos, F. Slouik, A. Boiardi, A. Salmaggi, A. Pozzi, L. Farinotti, L. Fariselli, A. Silvani, A. Brandes, E. Scelzi, A. Rigon, P. Zampieri, M. Pignataro, P. D'. Amanzo, P. Amista, A. Rotilio, M. V. Fiorentino, R. Thomas, L. Brazil, A. M. O'Connor, Maurizio Salvati, Fabrizio Puzzilli, Michele Raguso, R. Duckworth, R. Rumpling, M. Rottuci, G. Broggi, N. G. Plrint, E. Sabattini, V. Manetto, H. Gambacorta, S. Poggi, S. Pileri, R. Ferracini, D. V. Plev, N. J. Hopf, E. Knosp, J. Bohl, A. Perncczky, I. Catnby, O. Dewitte, J. L. Pasteels, I. Camby, F. Darro, A. Danguy, M. C. Kiu, G. M. Lai, T. S. Yang, K. T. Ng, J. S. Chen, C. N. Chang, W. M. Leung, Y. S. Ho, M. Deblec Rychter, A. Klimek, P. P. Liberski, A. Karpinaka, P. Krauseneck, V. Schöffel, B. Müller, F. W. Kreth, M. Faist, P. C. Warnke, C. B. Ostertag, K. M. B. v. Nielen, M. C. Visscr, C. Lebrun, M. Lonjon, T. Desjardin, J. F. Michiels, Sa. Lagrange J. L. Chanalet, J. L. Roche, M. Chatel, L. Mastronardi, F. Puzzilli, Farah J. Osman, P. Lunardi, M. Matsutani, Y. Ushio, K. Takakura, Johan Menten, Han Hamers, Jacques Ribot, René Dom, Hans Tcepen, N. Weidner, G. Naujocks, D. van Roost, O. D. Wiestler, A. Kuncz, C. Nieder, M. Setzel-Sesterhein, M. Niewald, I. Schnabel, K. S. O'Neill, N. D. Kitchen, P. R. Wilkins, H. T. Marsh, E. Pierce, R. Doshi, R. Deane, S. Previtali, A. Quattrini, R. Nemni, A. Ducati, L. Wrabetz, N. Canal, C. J. A. Punt, L. Stamatakis, B. Giroux, E. Rutten, Matthew R. Quigley, P. A. -C. Beth Sargent, Nicholas Flores, Sheryl Simon, Joseph C. Maroon, A. A. Rocca, C. Gervasoni, A. Castagna, P. Picozzi, E. Giugni, G. P. Tonnarelli, F. Mangili, G. Truci, M. Giovanelli, W. Sachsenheimer, T. Bimmler, H. Rhomberg W. Eiter, A. Obwegesser, H. Steilen, W. Henn, J. R. Moringlane, H. Kolles, W. Feiden, K. D. Zang, W. I. Sleudel, Andreas Steinbrecher, Martin Schabet, Clemens Heb, Michael Bamberg, Johannes Dichgans, G. Stragliotto, J. Y. Delattre, M. Poisson, L. Tosatto, P. D'Amanzo, N. Menicucci, S. Mingrino, W. I. Steudel, R. Feld, J. Ph. Maire, M. Caudry, J. Guerin, D. Celerier, N. Salem, H. Demeaux, J. F. Fahregat, M. E. Kusak, A. Bucno, J. Albisua, P. Jerez, J. L. Sarasa, R. Garefa, J. M. de Campos, A. Bueno, R. García-Delgado, R. García-Sola, A. A. Lantsov, T. I. Shustova, D. Lcnartz, R. Wellenreuther, A. von Deirnling, W. Köning, J. Menzel, S. Scarpa, A. Manna, M. G. Reale, P. A. Oppido, L. Frati, C. A. Valery, M. Ichen, J. P. Foncin, C. Soubrane, D. Khayat, J. Philippon, R. Vaz, C. Cruz, S. Weis, D. Protopapa, R. März, P. A. Winkler, H. J. Reulen, K. Bise, E. Beuls, J. Berg, W. Deinsberger, M. Samii, V. Darrouzet, J. Guérin, R. Trouette, N. Causse, J. P. Bébéar, F. Parker, J. N. Vallee, R. Carlier, M. Zerah, C. Lacroix-Jousselin, Joseph M. Piepmeier, John Kveton, Agnes Czibulka, G. S. Tigliev, M. P. Chernov, L. N. Maslova, José M. Valdueza, Werner Jänisch, Alexander Bock, Lutz Harms, E. M. Bessell, F. Graus, J. Punt, J. Firth, T. Hope, Osama Koriech, Saleh Al Deeb, Khalaf Al Moutaery, B. Yaqub, A. Franzini, R. Goldbrunner, M. Warmuth-Metz, W. Paulus, J. -Ch. Tonn, I. I. Strik, C. Markert, K. -W. Pflughaupt, B. P. O'Neill, R. P. Dinapoli, J. Voges, V. Sturm, U. Deuß, C. Traud, H. Treuer, R. Lehrke, D. G. Kim, R. P. Müller, Yu. S. Alexandrov, K. Moutaery, M. Aabed, O. Koreich, G. M. Ross, D. Ford, I. L. O. Schmeets, J. J. Jager, M. A. G. Pannebakker, J. M. A. de Jong, E. van Lindert, K. Kitz, S. Blond, F. Dubois, R. Assaker, M. C. Baranzelli, M. Sleiman, J. P. Pruvo, B. Coche-Dequeant, K. Sano, G. PetriČ-Grabnar, B. Jereb, N. Župančič, M. Koršič, N. G. Rainov, W. Burkert, Yukitaka Ushio, Masato Kochi, Youichi Itoyama, R. García, L. Ferrando, K. Hoang-Xuan, M. Sanson, P. Merel, O. Delattre, G. Thomas, D. Haritz, B. Obersen, F. Grochulla, D. Gabel, K. Haselsberger, H. Radner, G. Pendl, R. W. Laing, A. P. Warrington, P. J. C. M. Nowak, I. K. K. Kolkman-Deurloo, A. G. Visser, Hv. d. Berge, C. G. J. H. Niël, P. Bergström, M. Hariz, P. -O. Löfroth, T. Bergenheim, C. Cortet-rudelli, D. Dewailly, B. Coche-dequeant, B. Castelain, R. Dinapoli, E. Shaw, R. Coffey, J. Earle, R. Foote, P. Schomberg, D. Gorman, N. Girard, M. N. Courel, B. Delpech, G. M. Friehs, O. Schröttner, R. Pötter, R. hawliczek, P. Sperveslage, F. J. Prott, S. Wachter, K. Dieckmann, B. Bauer, R. Jund, F. Zimmermann, H. J. Feldmann, P. Kneschaurek, M. Molls, G. Lederman, J. Lowry, S. Wertheim, L. Voulsinas, M. Fine, I. Voutsinas, G. Qian, H. Rashid, P. Montemaggi, R. Trignani, C. West, W. Grand, C. Sibata, D. Guerrero, N. James, R. Bramer, H. Pahlke, N. Banik, M. Hövels, H. J. J. A. Bernsen, P. F. J. W. Rijken, B. P. J. Van der Sanden, N. E. M. Hagemeier, A. J. Van der Kogel, P. J. Koehler, H. Verbiest, J. Jager, A. McIlwrath, R. Brown, C. Mottolesb, A. Pierre'Kahn, M. Croux, J. Marchai, P. Delhemes, M. Tremoulet, B. Stilhart, J. Chazai, P. Caillaud, R. Ravon, J. Passacha, E. Bouffet, C. M. F. Dirven, J. J. A. Mooy, W. M. Molenaar, G. M. Lewandowicz, N. Grant, W. Harkness, R. Hayward, D. G. T. Thomas, J. L. Darling, N. Delepine, I. I. Subovici, B. Cornille, S. Markowska, JC. Desbois Alkallaf, J. KühI, D. Niethammer, H. J. Spaar, A. Gnekow, W. Havers, F. Berthold, N. Graf, F. Lampert, E. Maass, R. Mertens, V. Schöck, A. Aguzzi, A. Boukhny, S. Smirtukov, A. Prityko, B. Hoiodov, O. Geludkova, A. Nikanorov, P. Levin, B. D'haen, F. Van Calenbergh, P. Casaer, R. Dom, J. Menten, J. Goffin, C. Plets, A. Hertel, P. Hernaiz, C. Seipp, K. Siegler, R. P. Baum, F. D. Maul, D. Schwabe, G. Jacobi, B. Kornhuber, G. Hör, A. Merzak, H. K. Rooprai, P. Bullock, P. H. M. F. van Domburg, P. Wesseling, H. O. M. Thijssen, J. E. A. Wolff, J. Boos, K. H. Krähling, V. Gressner-Brocks, H. Jürgens, J. Schlegel, H. Scherthan, N. Arens, Gabi Stumm, Marika Kiessling, S. Koochekpour, G. Reifenberger, J. Reifenberger, L. Liu, C. D. James, W. Wechsler, V. P. Collins, Klaus Fabel-Schulte, Plotr Jachimczak, Birgitt Heßdörfer, Inge Baur, Karl -Hermann Schlingensiepen, Wolgang Brysch, A. Blesch, A. K. Bosserhoff, R. Apfel, F. Lottspeich, R. Büttner, R. Cece, I. Barajon, S. Tazzari, G. Cavaletti, L. Torri-Tarelli, G. Tredici, B. Hecht, C. Turc-Carel, R. Atllas, P. Gaudray, J. Gioanni, F. Hecht, J. A. Rey, M. J. Bello, M. Parent, P. Gosselin, J. L. Christiaens, J. R. Schaudies, M. Janka, U. Fischer, E. Meese, M. Remmelink, P. Cras, R. J. Bensadoun, M. Frenay, J. L. Formento, G. Milano, J. L. Lagrange, P. Grellier, J. -Y. Lee, H. -H. Riese, J. Cervós-Navarro, W. Reutter, B. Lippitz, C. Scheitinger, M. Scholz, J. Weis, J. M. Gilsbach, L. Füzesi, Y. J. Li, R. Hamelin, Erik Van de Kelft, Erna Dams, Jean -Jacques Martin, Patrick Willems, J. Erdmann, R. E. Wurm, S. Sardell, J. D. Graham, Jun -ichi Kuratsu, M. Aichholzer, K. Rössler, F. Alesch, A. Ertl, P. S. Sorensen, S. Helweg-Larsen, H. Mourldsen, H. H. Hansen, S. Y. El Sharoum, M. W. Berfelo, P. H. M. H. Theunissen, I. Fedorcsák, I. Nyáry, É. Osztie, Á. Horvath, G. Kontra, J. Burgoni-chuzel, P. Paquis, SW. Hansen, PS. Sørensen, M. Morche, F. J. Lagerwaard, W. M. H. Eijkenboom, P. I. M. Schmilz, S. Lentzsch, F. Weber, J. Franke, B. Dörken, G. Schettini, R. Qasho, D. Garabello, S. Sales, R. De Lucchi, E. Vasario, X. Muracciole, J. Régis, L. Manera, J. C. Peragut, P. Juin, R. Sedan, K. Walter, K. Schnabel, N. Niewald, U. Nestle, W. Berberich, P. Oschmann, R. D. Theißen, K. H. Reuner, M. Kaps, W. Dorndorf, K. K. Martin, J. Akinwunmi, A. Kennedy, A. Linke, N. Ognjenovic, A. I. Svadovsky, V. V. Peresedov, A. A. Bulakov, M. Y. Butyalko, I. G. Zhirnova, D. A. Labunsky, V. V. Gnazdizky, I. V. Gannushkina, M. J. B. Taphoorn, R. Potman, F. Barkhof, J. G. Weerts, A. B. M. F. Karim, J. J. Heimans, M. van de Pol, V. C. van Aalst, J. T. Wilmink, J. J. van der Sande, W. Boogerd, R. Kröger, A. Jäger, C. Wismeth, A. Dekant, W. Brysch, K. H. Schlingensiepen, B. Pirolte, V. Cool, C. Gérard, J. L. Dargent, T. Velu, U. Herrlinger, M. Schabet, P. Ohneseit, R. Buchholz, Jianhong Zhu, Regina Reszka, Friedrich Weber, Wolfgang Walther, L. I. Zhang, Mario Brock, J. P. Rock, H. Zeng, J. Feng, J. D. Fenstermacher, A. Gabizon, M. Beljanski, S. Crochet, B. Zackrisson, J. Elfverson, G. Butti, R. Baetta, L. Magrassi, M. R. De Renzis, M. R. Soma, C. Davegna, S. Pezzotta, R. Paoletti, R. Fumagalli, L. Infuso, A. A. Sankar, G. -L. Defer, P. Brugières, F. Gray, C. Chomienne, J. Poirier, L. Degos, J. D. Degos, Bruno M. Colombo, Stefano DiDonato, Gaetano Finocchiaro, K. M. Hebeda, H. J. C. M. Sterenborg, A. E. Saarnak, J. G. Wolbers, M. J. C. van Gemert, P. Kaaijk, D. Troost, S. Leenstra, P. K. Das, D. A. Bosch, B. W. Hochleitner, A. Obwegeser, W. Vooys, G. C. de Gast, J. J. M. Marx, T. Menovsky, J. F. Beek, V. Schirrmacher, A. Schmitz, A. M. Eis-Hübinger, p. h. Piepmeier, Patricia Pedersen, Charles Greer, Tommy Shih, Amr Elrifal, William Rothfus, L. Rohertson, R. Rampling, T. L. Whoteley, J. A. Piumb, D. J. Kerr, P. A. Falina, I. M. Crossan, K. L. Ho, M. M. Ruchoux, S. Vincent, F. Jonca, J. Plouet, M. Lecomte, D. Samid, A. Thibault, Z. Ram, E. H. Oldfield, C. E. Myers, E. Reed, Y. Shoshan, Tz. Siegal, G. Stockhammer, M. Rosenblum, F. Lieberman, A. J. A. Terzis, R. Bjerkvig, O. D. Laerum, H. Arnold, W. D. Figg, G. Flux, S. Chittenden, P. Doshi, D. Bignor, M. Zalutsky, Juri Tjuvajev, Michael Kaplitt, Revathi Desai, M. S. Bradley, B. S. Bettie, Bernd Gansbacher, Ronald Blasberg, H. K. Haugland, J. Saraste, K. Rooseni, A. J. P. E. Vincent, C. J. J. Avezaat, A. Bout, J. L. Noteboom, C. h. Vecht, D. Valerio, P. M. Hoogerbrugge, R. Reszka, J. Zhu, W. Walther, J. List, W. Schulz, I. I. J. C. M. Sterenborg, W. Kamphorst, H. A. M. van Alplien, P. Salander, R. Laing, B. Schmidt, G. Grau, T. Bohnstedt, A. Frydrych, K. Franz, R. Lorenz, F. Berti, A. Paccagnella, P. L. van Deventer, P. L. I. Dellemijn, M. J. van den Bent, P. J. Kansen, N. G. Petruccioli, E. Cavalletti, B. Kiburg, L. J. Müller, C. M. Moorer-van Delft, H. H. Boer, A. Pace, L. Bove, A. Pietrangeli, P. Innocenti, A. Aloe, M. Nardi, B. Jandolo, S. J. Kellie, S. S. N. De Graaf, H. Bloemhof, D. Roebuck, Pozza L. Dalla, D. D. R. Uges, I. Johnston, M. Besser, R. A. Chaseling, S. Koeppen, S. Gründemann, M. Nitschke, P. Vieregge, E. Reusche, P. Rob, D. Kömpf, T. J. Postma, J. B. Vermorken, R. P. Rampling, D. J. Dunlop, M. S. Steward, S. M. Campbell, S. Roy, P. H. E. Hilkens, J. Verweij, W. L. J. van Putten, J. W. B. Moll, M. E. L. van der Burg, A. S. T. Planting, E. Wondrusch, U. Zifko, M. Drlicek, U. Liszka, W. Grisold, B. Fazeny, Ch. Dittrich, Jan J. Verschuuren, Patricio I. Meneses, Myrna R. Rosenfeld, Michael G. Kaplitt, Jerome B. Posner, Josep Dalmau, P. A. E. Sillevis Smitt, G. Manley, J. B. Posner, G. Bogliun, L. Margorati, G. Bianchi, U. Liska, B. Casati, C. Kolig, H. Grisold, R. Reñe, M. Uchuya, F. Valldeoriola, C. Benedetti de Cosentiro, D. Ortale, R. Martinez, J. Lambre, S. Cagnolati, C. Vinai, M. G. Forno, R. Luksch, P. Confalonieri, J. Scholz, G. Pfeiffer, J. Netzer, Ch. Hansen, Ch. Eggers, Ch. Hagel, K. Kunze, Marc K. Rosenblum, and Frank S. Lieberman
- Subjects
Cancer Research ,Neurology ,Oncology ,Neurology (clinical) - Published
- 1994
- Full Text
- View/download PDF
14. Risk model for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens. The Elypse 1 Study Group
- Author
-
I, Ray-Coquard, A, Le Cesne, M T, Rubio, J, Mermet, C, Maugard, A, Ravaud, C, Chevreau, C, Sebban, T, Bachelot, P, Biron, and J Y, Blay
- Subjects
Adult ,Aged, 80 and over ,Male ,Analysis of Variance ,Adolescent ,Age Factors ,Anemia ,Antineoplastic Agents ,Hemoglobin A ,Middle Aged ,Severity of Illness Index ,Cohort Studies ,Logistic Models ,Risk Factors ,Neoplasms ,Humans ,Female ,Erythrocyte Transfusion ,Aged ,Probability ,Retrospective Studies - Abstract
Cancer patients frequently experience anemia as a consequence of myelosuppressive therapy or bone marrow invasion.A risk model for chemotherapy-induced severe anemia requiring RBC transfusions (SARRT) within 31 days after the administration of chemotherapy was delineated in the cohort of cancer patients treated with chemotherapy in the Department of Medicine of Centre Léon Bérard in 1996 (CLB-1996). The risk model was tested on a series of 797 patients treated in 1997 (CLB-1997) and on 295 patients included in a multicenter prospective series (ELYPSE 1).One hundred seven of the 1,051 patients of the CLB-1996 cohort (10%) experienced SARRT. In univariate analysis, only female sex, performance status greater than 1, hemoglobin level less than 12 g/dL before chemotherapy on day 1 (d1), and d1 lymphocyte countor = 700/microL significantly correlated with the risk of SARRT. Using logistic regression, d1 hemoglobin level less than 12 g/dL (odds ratio [OR] = 14.0; 95% confidence interval [CI], 7 to 30), performance status greater than 1 (OR = 2.2; 95% CI, 1.4 to 3.5), and d1 lymphocyte countor = 700/microL (OR = 1.7; 95% CI, 1. 1 to 2.6) were identified as independent risk factors for SARRT. These three factors were given arbitrary risk coefficients of 3, 1, and 1 respectively, and a risk score for each individual patient was obtained by adding the coefficients. The calculated probability of RBC transfusions was 30% for patients with a scoreor = 4, and 11%, 4%, and 1% in patients with a score of 2 or 3, 1, and 0 respectively. This model was then tested and validated in the CLB-1997 and ELYPSE 1 series.This risk index could be useful to identify patients at high risk for chemotherapy-induced SARRT who might be appropriate candidates for prophylactic erythropoietin treatment.
- Published
- 1999
15. Cancer genetic clinics: why do women who already have cancer attend?
- Author
-
M. Machelard, Y J Bignon, Hagay Sobol, C. Maugard, Claire Julian-Reynier, Catherine Noguès, Françoise Chabal, François Eisinger, Y. Aurran, and Philippe Vennin
- Subjects
Cancer Research ,medicine.medical_specialty ,Genetic counseling ,Breast Neoplasms ,Genetic Counseling ,Social epidemiology ,Disease ,Cancer Care Facilities ,Lower risk ,medicine.disease_cause ,Risk Factors ,Heredity ,Epidemiology ,Medicine ,Humans ,Referral and Consultation ,Gynecology ,Ovarian Neoplasms ,business.industry ,Cancer ,Middle Aged ,Patient Acceptance of Health Care ,medicine.disease ,Oncology ,Patient Satisfaction ,Family medicine ,Etiology ,Female ,France ,business ,Attitude to Health - Abstract
Cancer patients attend oncogenetic clinics so that the existence of a genetic risk can be checked and the relatives informed. The aim of this study was to describe the expectations of cancer patients about genetic counselling and their beliefs about the aetiology of their disease. A survey based on self-administered questionnaires before and after the consultation was carried out on 115 women with breast/ovarian cancer who attended one of the six French participating clinics. In 59 cases (51)%, the consultees' expectations focused on the preventive options available and in 86 cases (75%) on their offspring; 87 (76%) found the consultation informative. On average, the women rated heredity and diet as lower risk factors (P< 0.05) after the consultation than before. Heredity, stress and the environment were thought to be more decisive than diet, smoking and alcohol. 34 patients who seemed unlikely to have a genetic risk in the consultant's opinion thought heredity to be less relevant (P< 0.05) after the consultation than before. At the time of the survey, cancer patients accounted for at least half of the consultees attending oncogenetic clinics in France. They need to have the clinical specificities of their disease and its medical management explained. They attend mainly for their offspring's sake, whereas healthy clients attend for their own sake.
- Published
- 1999
16. Marker segregation information in breast/ovarian cancer genetic counseling: is it still useful? Groupe Génétique et Cancer de la Fédération Nationale des Centres de Lutte Contre le Cancer
- Author
-
L, Essioux, C, Girodet, O, Sinilnikova, S, Pagès, F, Eisinger, S, de Résende, C, Maugard, D, Lanoë, M, Longy, Y J, Bignon, H, Sobol, C, Bonaïti-Pellié, and D, Stoppa-Lyonnet
- Subjects
BRCA2 Protein ,Ovarian Neoplasms ,Heterozygote ,BRCA1 Protein ,Genetic Linkage ,Breast Neoplasms ,Genetic Counseling ,Neoplasm Proteins ,Pedigree ,Chromosome Segregation ,Biomarkers, Tumor ,Humans ,Female ,Genetic Testing ,Transcription Factors - Abstract
The use of mutation screening of BRCA1 and BRCA2 genes as a genetic test is still to a certain extent limited and the oncogeneticist may want to use complementary approaches to identify at-risk individuals. In a series of 23 families with at least three breast or ovarian cancer cases, screened for mutations at BRCA1 and BRCA2 and typed for markers at both loci, we investigated the usefulness of marker segregation information at two levels: 1) to what extent can the indirect approach identify the mutation carrier status of screened cases and their first-degree relatives, and 2) in what way does it help to identify the gene implicated in a family in which neither BRCA1 nor BRCA2 mutation has been detected? Using the indirect approach, the carrier status of the screened case could be determined with quasi certainty in three families and with a high probability in eight families. This status could be inferred in unaffected first-degree relatives as almost certain in one family and as highly probable in six families. Fourteen mutations were found concurrently in our series. Among the nine mutation-negative families, we were able to conclude that a BRCA1 mutation most probably segregated in one and that a mutation other than BRCA1 and BRCA2 was probably involved in two families. Our results show that, in small families, little help is to be expected from linkage data and mutation screening is the only way of identifying the origin of a genetic predisposition in a family. Marker segregation information may be useful in some large breast/ovarian cancer families in which no BRCA1 or BRCA2 mutation has been detected.
- Published
- 1998
17. A risk model for thrombocytopenia requiring platelet transfusion after cytotoxic chemotherapy
- Author
-
Alain Ravaud, C. Mermet, C. Maugard, Jean-Paul Guastalla, Catherine Sebban, J.-Y. Blay, I.L. Ray-Coquard, Christine Chevreau, A. Le Cesne, and P. Biron
- Subjects
Adult ,Male ,Risk ,medicine.medical_specialty ,Side effect ,medicine.medical_treatment ,Immunology ,Platelet Transfusion ,Gastroenterology ,Biochemistry ,Risk Factors ,Internal medicine ,Neoplasms ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Risk factor ,Aged ,Chemotherapy ,Univariate analysis ,Performance status ,business.industry ,Cell Biology ,Hematology ,Middle Aged ,Chemotherapy regimen ,Thrombocytopenia ,Surgery ,Platelet transfusion ,Cohort ,Regression Analysis ,Female ,business - Abstract
Severe thrombocytopenia is a rare but life-threatening side effect of cytotoxic chemotherapy for which risk factors are not well known. Our objective was to delineate a risk model for chemotherapy-induced thrombocytopenia requiring platelet transfusions in cancer patients. Univariate and multivariate analysis of risk factors for chemotherapy-induced thrombocytopenia requiring platelet transfusions were performed on the cohort of the 1,051 patients (CLB 1996) treated with chemotherapy in the Department of Medicine of the Centre Léon Bérard (CLB) in 1996. In univariate analysis, performance status (PS) greater than 1, platelet count less than 150,000/μL at day 1 (d1) before the initiation of chemotherapy, d1 lymphocyte count ≤700/μL, d1 polymorphonuclear leukocyte count less than 1,500/μL, and the type of chemotherapy (high risk v others) were significantly associated (P < .01) with an increased risk of severe thrombocytopenia requiring platelet transfusions. Using logistic regression, d1 platelet count less than 150,000/μL (odds ratio [OR], 4.3; 95% confidence interval [CI], 1.9 to 9.6), d1 lymphocyte counts ≤700/μL (OR, 3.37; 95% CI, 1.77 to 6.4), the type of chemotherapy (OR, 3.38; 95% CI, 1.77 to 6.4), and PS greater than 1 (OR, 2.23; 95% CI, 1.22 to 4.1) were identified as independent risk factors for platelet transfusions. The observed incidences of platelet transfusions were 45%, 13%, 7%, and 1.5% for patients with ≥3, 2, 1, or 0 risk factors, respectively. This model was then tested in 3 groups of patients treated with chemotherapy used as validation samples: (1) the series of 340 patients treated in the CLB in the first 6 months of 1997, (2) the prospective multicentric cohort of 321 patients of the ELYPSE 1 study, and (3) the series of 149 patients with non-Hodgkin's lymphoma treated in the CLB within prospective phase III trials (1987 to 1995). In these 3 groups, the observed incidences of platelet transfusions in the above-defined risk groups did not differ significantly (P > .1) from those calculated in the model. This risk index could be useful to identify patients at high risk for chemotherapy-induced thrombocytopenia requiring platelet transfusions.
- Published
- 1998
18. Pathology of sporadic breast tumors with LOH at the BRCA1 locus: correlation with histopathological features specific to familial BRCA1 tumors and absence of microsatellite instability
- Author
-
C. Vaurs-Barriere, Véronique Vidal, Fabrice Kwiatkowski, Y J Bignon, Frédérique Penault-Llorca, and C. Maugard
- Subjects
Adult ,Cancer Research ,medicine.medical_specialty ,Pathology ,endocrine system diseases ,Mammary gland ,Genes, BRCA1 ,Loss of Heterozygosity ,Breast Neoplasms ,Locus (genetics) ,Biology ,Severity of Illness Index ,Loss of heterozygosity ,Gene Frequency ,medicine ,Carcinoma ,Humans ,skin and connective tissue diseases ,Alleles ,Aged ,Aged, 80 and over ,Family Health ,Cytogenetics ,Cancer ,Microsatellite instability ,Middle Aged ,medicine.disease ,medicine.anatomical_structure ,Oncology ,Cancer research ,Microsatellite ,Female ,Microsatellite Repeats - Abstract
To investigate the coordinated occurrence of loss of heterozygosity (LOH) at the BRCA1 locus and microsatellite instability (MI) in sporadic breast carcinomas, 56 tumors were analysed for both genetic alterations. The comparison of clinicopathological features with the obtained data revealed that LOH at the BRCA1 locus was significantly correlated with features specific for familial BRCA1 tumors and with absence of hormone receptors. No correlation was found between LOH and MI. These results suggest that sporadic and familial breast tumors, where BRCA1 is altered, could display similar clinicopathological features and that LOH and MI are distinct genetic events in sporadic breast carcinogenesis.
- Published
- 1998
- Full Text
- View/download PDF
19. 116 Higher incidence of patients with a positive family history of prostate cancer than expected amongst French Canadians
- Author
-
Daniel Taussky, Jean-Paul Bahary, Edith Filion, and C. Maugard
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,Incidence (epidemiology) ,Hematology ,medicine.disease ,Prostate cancer ,Internal medicine ,Family medicine ,medicine ,French canadian ,Radiology, Nuclear Medicine and imaging ,Family history ,business - Published
- 2006
- Full Text
- View/download PDF
20. French multicentric evaluation of mdr1 gene expression by RT-PCR in leukemia and solid tumours. Standardization of RT-PCR and preliminary comparisons between RT-PCR and immunohistochemistry in solid tumours. French Network of the Drug Resistance Intergroup, and Drug Resistance Network of Assistance Publique-Hôpitaux de Paris
- Author
-
S, Chevillard, P, Vielh, P, Validire, J P, Marie, A M, Faussat, V, Barbu, C, Bayle, J, Bénard, C, Bonnal, J, Boutonnat, F, Calvo, J, Charrier, A, Clary, P, Colosetti, L, Danel-Moore, P, Decrémoux, C, Delvincourt, F, Finat-Duclos, P, Genne, A, Kataki, J C, Kouyoumdjian, R, Lacave, C, Maugard, J L, Merlin, and J, Robert
- Subjects
DNA, Complementary ,Leukemia ,Neoplasms ,Humans ,RNA ,ATP Binding Cassette Transporter, Subfamily B, Member 1 ,Immunohistochemistry ,Polymerase Chain Reaction - Abstract
Since there is no consensus on the techniques for multidrug resistance (MDR) phenotype evaluation, many discrepancies concerning the importance and frequency of mdr1 gene expression in leukemias and solid tumors are observed in the literature. In order to establish an inter-laboratory consensus in France, a multicenter study was carried out to propose further guidelines for MDR phenotype evaluation. The techniques used by the 38 laboratories participating in the trial were: immunodetection (immunohisto and/or cytochemistry, flow cytometry), functional tests, reverse transcription-polymerase chain reaction (RT-PCR) or Northern blot. We present the results obtained by 19 laboratories concerning the measurement of mdr1 gene expression assessed by RT-PCR or Northern blot in: (1)19 samples of tumor cells obtained from leukemic patients; (2) six solid tumor samples obtained at surgery; (3) eight cell lines exhibiting variable levels of resistance, and; (4)10 preparations of RNA and of cDNA obtained from solid tumors. Standardization of the RT-PCR technique and preliminary results comparing RT-PCR with immunohistochemistry in solid tumors are also reported.
- Published
- 1997
21. BRCA2 mutations in hereditary breast and ovarian cancer in France
- Author
-
O M, Serova-Sinilnikova, L, Boutrand, D, Stoppa-Lyonnet, B, Bressac-de-Paillerets, V, Dubois, C, Lasset, N, Janin, Y J, Bignon, M, Longy, C, Maugard, R, Lidereau, D, Leroux, T, Frebourg, S, Mazoyer, and G M, Lenoir
- Subjects
Adult ,BRCA2 Protein ,Male ,Ovarian Neoplasms ,Letter ,Mutation ,Humans ,Breast Neoplasms ,Female ,France ,Middle Aged ,Neoplasm Proteins ,Transcription Factors - Published
- 1997
22. Loss of heterozygosity at 7q31 in breast cancer: results from an International Collaborative Study Group. The Breast Cancer Somatic Genetics Consortium
- Author
-
P, Devilee, J, Hermans, J, Eyfjörd, A L, Bøorresen, R, Lidereau, H, Sobol, A, Borg, A M, Cleton-Jansen, E, Oláh, B B, Cohen, S, Scherneck, U, Hamann, B, Peterlin, M, Caligo, Y J, Bignon, and C, Maugard
- Subjects
Chromosome Aberrations ,Europe ,Heterozygote ,Humans ,Breast Neoplasms ,DNA, Neoplasm ,Prognosis ,Survival Analysis ,Chromosomes, Human, Pair 7 ,Microsatellite Repeats - Abstract
Loss of heterozygosity (LOH) at 7q31 has been claimed to occur in over 80% of all breast cancers and to be of prognostic significance. This would make this genetic alteration the most common event observed in breast cancer to date. Others, however, have been unable to confirm this high incidence. In this multicenter study, we have complied LOH scorings for three polymorphic markers for 7q31-q32 in 683 breast tumors. Although some significant differences between centers existed, no center reported more than 40% LOH, and the average rate was 19%. Disease-free and overall survival of the patients whose tumors carried LOH at 7q31 did not differ significantly from those patients whose tumors showed retention of heterozygosity at 7q31. In a double-blind scoring of a subset of the raw data, an average discordant rate of LOH scoring of 12% was observed. While startling in itself, this was unable to explain the variation among centers, nor the difference with the initially reported high rate of LOH. We conclude that LOH at 7q31 is not important as a genetic alteration in breast cancer as originally suggested, nor a strong determinant of disease outcome.
- Published
- 1997
23. A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC
- Author
-
P. Kerbrat, Y. Krakowski, P. Fumoleau, N. Azli, B. Chevallier, A. Riva, J. L. Misset, N. Bougon, Henri Roché, C. Maugard-Louboutin, and Véronique Diéras
- Subjects
Adult ,medicine.medical_specialty ,Paclitaxel ,medicine.medical_treatment ,Breast Neoplasms ,Docetaxel ,Gastroenterology ,Internal medicine ,medicine ,Confidence Intervals ,Humans ,Infusions, Intravenous ,Aged ,Chemotherapy ,Performance status ,Dose-Response Relationship, Drug ,business.industry ,Hematology ,Middle Aged ,medicine.disease ,Chemotherapy regimen ,Antineoplastic Agents, Phytogenic ,Surgery ,Survival Rate ,Regimen ,Treatment Outcome ,Oncology ,Tolerability ,Premedication ,Female ,Taxoids ,business ,Febrile neutropenia ,medicine.drug - Abstract
Summary Background Two previous phase II trials of docetaxel as first line chemotherapy of advanced breast cancer have been conducted by the Clinical Screening Group of the EORTC. In these 2 studies, docetaxel 100 mg/m2 and 75 mg/m2 were administered without routine premedication and produced overall response rates of 68% and 52% respectively. Fluid retention was the most problematic adverse event in these 2 studies in which premedication was not routinely administered. This study investigated the efficacy and safety profile of docetaxel with a 1-day prophylactic premedication. Patients and methods Docetaxel 100 mg/m2 was administered intravenously over 1 hour, every 3 weeks, to 37 women (aged 29–65 years) with advanced breast cancer. A 1-day regimen of intravenous antihistamine and oral corticoster-oids was given with each dose. Full doses of docetaxel were administered in 179 of 200 cycles (89.5%), giving a median relative dose intensity of 0.98. Results Tumour regression was achieved in 25 patients (67.6%) after a median of 7 weeks, and 2 patients (5.4%) had a complete response. Response rates were 67.9% in patients with visceral metastases, 76.9% in liver metastases and 83.3% in patients with > 2 organs involved. The median time to progression was 31 weeks (range 1–36+). After a median follow-up time of 6.9 months (range 4.6–9.4), 31 patients (83.7%) were still alive. The most common adverse events (AE) were neutropenia (97%), alopecia (97%, grade 1–2), fluid retention (89%, mainly mild to moderate) and neurosensory disorders (81%, mainly mild to moderate). Only 5 patients experienced febrile neutropenia requiring hospitalisation and/or antibiotic therapy. Sixteen patients discontinued treatment because of fluid retention; nevertheless, 13 of these achieved an objective antitumour response and none had any significant deterioration in performance status. AEs were generally reversible and easily managed, and there were no deaths attributable to docetaxel-related AEs. Conclusions Docetaxel produces very effective tumour response with acceptable tolerability when used as first-line chemotherapy in patients with advanced breast cancer. The 1-day premedication regimen used in this study was less effective in reducing the incidence and severity or delaying the onset of fluid retention than the currently recommended 5-day corticosteroid premedication. The optimum premedication regimen remains to be defined.
- Published
- 1996
24. Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity
- Author
-
Antoine Thyss, B. Bui, B. Chevallier, A.M. Peny, Pierre Fargeot, Didier Cupissol, C Maugard-Louboutin, I. Krakowski, Christine Chevreau, and F. Bonichon
- Subjects
Oncology ,Male ,Cancer Research ,medicine.medical_treatment ,Soft Tissue Neoplasms ,chemistry.chemical_compound ,Hemoglobins ,Leukocyte Count ,Antineoplastic Combined Chemotherapy Protocols ,Granulocyte Colony-Stimulating Factor ,Mesna ,Ifosfamide ,Soft tissue sarcoma ,Nausea ,Sarcoma ,Middle Aged ,Nitrogen mustard ,Recombinant Proteins ,Granulocyte colony-stimulating factor ,Dacarbazine ,Regression Analysis ,Female ,medicine.drug ,Adult ,medicine.medical_specialty ,Neutropenia ,Injections, Subcutaneous ,Lenograstim ,Double-Blind Method ,Internal medicine ,medicine ,Humans ,Aged ,Hematuria ,Chemotherapy ,Stomatitis ,business.industry ,Platelet Count ,Alopecia ,Length of Stay ,medicine.disease ,Surgery ,chemistry ,Doxorubicin ,business ,Follow-Up Studies - Abstract
PURPOSE This two-arm, double-blind, randomized trial was conducted to determine the effects of lenograstim, a glycosylated recombinant human granulocyte colony-stimulating factor (rHu-G-CSF), on the hematologic tolerance of patients with sarcoma treated with mesna, doxorubicin, ifosfamide, and doxorubicin (MAID) chemotherapy. PATIENTS AND METHODS Forty-eight patients with metastatic or locally advanced soft tissue sarcoma were, following the first cycle of a combination with doxorubicin 60 mg/m2, ifosfamide 7.5 g/m2, and dacarbazine 900 mg/m2, ifosfamide 7.5 g/m2, and dacarbazine 900 mg/m2 given on days 1 to 3, randomized to receive either lenograstim 5 micrograms/kg/d by once-daily injection from day 4 to day 13, or its vehicle. For subsequent cycles, 28 patients continued on the same chemotherapy and lenograstim was systematically given as prophylactic treatment in an open manner. RESULTS Following the first cycle of MAID, the duration of neutropenia was reduced in patients who received lenograstim as compared with those who received placebo, with a median duration of neutropenia ( < 0.5 x 10(9)/L neutrophils) of 0 days (range, 0 to 3) and 5 days (range, 0 to 10), respectively (P < .001). All patients who received lenograstim had recovered at least 1 x 10(9)/L neutrophils (polymorphonuclear lymphocytes [PMN]) on day 14, compared with only one of 26 in the placebo group (P < .001). The median time to recover this neutrophil level was 12 days (range, 10 to 13) and 17 days (range, 14 to 21), respectively (P < .001). Neutropenic fever occurred in five (23%) and 15 (58%) patients respectively (P = .02). Twenty-eight patients received at least two cycles (median, four) of MAID at the same dose. Toxicity remained constant across all treatment cycles. A progressive increase in thrombocytopenia was noted, with median platelet nadirs of 102 x 10(9)/L at cycle 2 and 19.5 x 10(9)/L at cycle 6, but did not result in significant treatment modifications. Consequently, median relative dose-intensities remained greater than 0.95 for up to six consecutive MAID cycles. CONCLUSION Lenograstim significantly improved hematologic tolerance in patients treated with the MAID chemotherapy regimen and, therefore, allowed optimal adhesion to the theoretic doses planned for up to six cycles. Whether such an optimization in relative dose-intensity will result in an improvement of treatment efficacy remains to be determined.
- Published
- 1995
25. [Paclitaxel (Taxol) and docetaxel (Taxotere): results of phase II trials in monochemotherapy]
- Author
-
P, Fumoleau, G, Perrocheau, C, Maugard-Louboutin, and B, Lemevel
- Subjects
Male ,Neutropenia ,Organoplatinum Compounds ,Paclitaxel ,Docetaxel ,Drug Tolerance ,Antineoplastic Agents, Phytogenic ,Drug Administration Schedule ,Drug Hypersensitivity ,Clinical Trials, Phase II as Topic ,Neoplasms ,Humans ,Female ,Taxoids - Abstract
The taxanes, paclitaxel and docetaxel, are the two presents clinically available representatives of a cytotoxic class with a new mechanism of action: they enhance microtubule assembly and inhibit their depolymerization. Their activity has been demonstrated in ovarian, breast and lung cancers. Paclitaxel and docetaxel are also promising agents in the treatment of head and neck, gastric and pancreatic cancer. Neutropenia is the dose limiting toxicity. Currently, use of premedication allows to circumvent hypersensitivity reactions encountered earlier with paclitaxel. For docetaxel, measures to prevent fluid retention are essential.
- Published
- 1995
26. [Well-differentiated papillary mesothelioma of the peritoneum: an attenuated malignant tumor. Review of the literature apropos of a case]
- Author
-
S, Bouvier, O, Baron, F, Nomballais, Y, Guillard, J C, Drianno, C, Maugard-Louboutin, B, Le Mevel, A Y, De Lajartre, and J L, Michaud
- Subjects
Mesothelioma ,Ovarian Neoplasms ,Neoplasms, Second Primary ,Middle Aged ,Prognosis ,Combined Modality Therapy ,Mediastinal Neoplasms ,Carcinoma, Papillary ,Pelvic Exenteration ,Diagnosis, Differential ,Humans ,Female ,Neoplasms, Glandular and Epithelial ,Peritoneal Neoplasms - Abstract
The authors present a new case of a well-differentiated papillary mesothelioma of the peritoneum. This is an uncommon tumor which have a slow evolution like a low malignant potential tumor. But, because of its tendency to recurrence, the designation of Well-Differentiated Tumor is better. The diagnosis with others peritoneal tumors is sometimes difficult, especially with the Peritoneal Serous Tumors. Tumor recurrence must be treated by curative surgery. Adjuvant therapy is discussed for the diffuse form.
- Published
- 1994
27. Leptomeningeal infiltration in esthesioneuroblastoma: report of two cases with poor prognosis
- Author
-
J.P. Louboutin, C. Maugard-Louboutin, and P. Fumoleau
- Subjects
Nasal cavity ,Male ,Pathology ,medicine.medical_specialty ,Poor prognosis ,animal structures ,Adolescent ,Esthesioneuroblastoma, Olfactory ,Fatal Outcome ,Meninges ,Esthesioneuroblastoma ,medicine ,Meningeal Neoplasms ,Humans ,Aged ,Olfactory Neuroblastoma ,business.industry ,Palliative Care ,food and beverages ,medicine.disease ,Prognosis ,Combined Modality Therapy ,medicine.anatomical_structure ,Meningeal carcinomatosis ,Neurology ,Chemotherapy, Adjuvant ,embryonic structures ,Female ,Neurology (clinical) ,Cranial Irradiation ,business ,Tomography, X-Ray Computed ,Infiltration (medical) ,Olfactory epithelium ,Paranasal Sinus Neoplasms - Abstract
Esthesioneuroblastoma is a rare neoplasm of neuroectodermal origin, arising from the olfactory epithelium in the roof of the nasal cavity. Extension to the brain can occur less frequently than local recurrence, but leptomeningeal metastases without brain involvement have rarely been mentioned. We report 2 cases with poor prognosis of leptomeningeal infiltration during the evolution of esthesioneuroblastoma.
- Published
- 1994
28. [Cancer of the breast]
- Author
-
C, Maugard-Louboutin
- Subjects
Adult ,Tamoxifen ,Antibiotics, Antineoplastic ,Paclitaxel ,Chemotherapy, Adjuvant ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Breast Neoplasms ,Female ,Middle Aged ,Neoplasm Metastasis - Abstract
Breast cancer remains a key concern for oncologists. The possibility of tamoxifen treatment to prevent breast cancer in high-risk women was one of the central topics discussed for the 1992 ASCO edition. The rationale for the studies being developed in the US and Europe rests on experimental data and results of adjuvant hormone therapy trials. Decreased risks of cancer in the opposite breast, of cardiovascular disease, and of osteoporosis are effects that make tamoxifen extremely attractive for breast cancer prevention trials in postmenopausal women. In premenopausal women, however, preventive tamoxifen should be viewed with special caution because increased incidence of second cancers have been reported, although with dosages higher than those suggested for preventive therapy, and also because of difficulties with defining familial forms. The value of anthracyclines for adjuvant therapy has been demonstrated by several studies. Furthermore, a dose-response relationship has been reported with anthracyclines used as adjuvant therapy or in metastatic disease. New dose-limiting toxic effects, including thrombocytopenia and mucitis, develop when dosages are increased, with concomitant rG-CSF therapy. In patients with metastases, taxol seems to be a promising drug. Ongoing phase I trials seek to determine the optimal dosage and administration modalities for the taxol-doxorubicin combination.
- Published
- 1992
29. [Genetics and cancers]
- Author
-
C, Maugard-Louboutin
- Subjects
Adult ,Chromosome Aberrations ,Male ,Ovarian Neoplasms ,Breast Neoplasms ,Chromosome Disorders ,Astrocytoma ,Middle Aged ,Genes, p53 ,Genes, DCC ,Chromosomes, Human, Pair 5 ,Humans ,Female ,Chromosomes, Human, Pair 18 ,Colorectal Neoplasms ,Aged ,Chromosomes, Human, Pair 17 - Abstract
Multiple genome alterations can be seen within a tumor and continue to accumulate throughout development of the growth. Chromosome deletions occurring in tumors are generating much interest. To date, the best known model is retinoblastoma whose study gave rise to the concepts of anti-oncogene or tumor suppressor gene. Studies of genetic anomalies in colorectal tumors have led to an elegant model of colonic carcinogenesis in which multiple steps, each with its corresponding genetic anomaly, successively accumulate, with deletion of the p53 gene occurring as a late event. Successive anomalies of the p53 gene (mutations, deletions) occur during passage from a low-grade astrocytoma to a higher-grade astrocytoma. Studies of familial forms of breast cancer and of breast and ovarian cancer have also provided insight into the biology of these tumors, with the identification of a predisposing chromosomal area whose location is 17 q-12-21. These approaches open up possibilities for screening techniques and use of preventive treatments in highly selected patients. However they raise many ethical problems. There is a need for developing a charter for these family studies in the near future.
- Published
- 1992
30. Risk Model for Severe Anemia Requiring Red Blood Cell Transfusion After Cytotoxic Conventional Chemotherapy Regimens
- Author
-
P. Biron, J.-Y. Blay, A. Le Cesne, Christine Chevreau, Alain Ravaud, M T Rubio, Catherine Sebban, Thomas Bachelot, I.L. Ray-Coquard, J Mermet, and C. Maugard
- Subjects
Cancer Research ,medicine.medical_specialty ,Chemotherapy ,Univariate analysis ,Performance status ,Anemia ,business.industry ,medicine.medical_treatment ,Retrospective cohort study ,Odds ratio ,medicine.disease ,Surgery ,Oncology ,Internal medicine ,medicine ,Risk factor ,business ,Cohort study - Abstract
PURPOSE: Cancer patients frequently experience anemia as a consequence of myelosuppressive therapy or bone marrow invasion. PATIENTS AND METHODS: A risk model for chemotherapy-induced severe anemia requiring RBC transfusions (SARRT) within 31 days after the administration of chemotherapy was delineated in the cohort of cancer patients treated with chemotherapy in the Department of Medicine of Centre Léon Bérard in 1996 (CLB-1996). The risk model was tested on a series of 797 patients treated in 1997 (CLB-1997) and on 295 patients included in a multicenter prospective series (ELYPSE 1). RESULTS: One hundred seven of the 1,051 patients of the CLB-1996 cohort (10%) experienced SARRT. In univariate analysis, only female sex, performance status greater than 1, hemoglobin level less than 12 g/dL before chemotherapy on day 1 (d1), and d1 lymphocyte count ≤ 700/μL significantly correlated with the risk of SARRT. Using logistic regression, d1 hemoglobin level less than 12 g/dL (odds ratio [OR] = 14.0; 95% confidence interval [CI], 7 to 30), performance status greater than 1 (OR = 2.2; 95% CI, 1.4 to 3.5), and d1 lymphocyte count ≤ 700/μL (OR = 1.7; 95% CI, 1.1 to 2.6) were identified as independent risk factors for SARRT. These three factors were given arbitrary risk coefficients of 3, 1, and 1 respectively, and a risk score for each individual patient was obtained by adding the coefficients. The calculated probability of RBC transfusions was 30% for patients with a score ≥ 4, and 11%, 4%, and 1% in patients with a score of 2 or 3, 1, and 0 respectively. This model was then tested and validated in the CLB-1997 and ELYPSE 1 series. CONCLUSION: This risk index could be useful to identify patients at high risk for chemotherapy-induced SARRT who might be appropriate candidates for prophylactic erythropoietin treatment.
- Published
- 1999
- Full Text
- View/download PDF
31. Le test de troncation des protéines (PTT) : un outil pour la détection de mutations dans l'ADN
- Author
-
Mireille Claustres, S Tuffery, C Maugard, L. Beaufrere, and C. Bareil
- Subjects
General Medicine ,Biology ,Molecular biology ,General Biochemistry, Genetics and Molecular Biology - Abstract
La detection de mutations dans l'ADN represente une etape essentielle de la biologie moleculaire, pour la recherche fondamentale comme pour les applications medicales. Les strategies actuellement disponibles pour deceler les alleles mutes sont fondees, soit sur l'utilisation de methodes rapides mais limitees a l'identification d'un nombre restreint de mutants determines, soit sur l'utilisation de techniques couteuses et laborieuses mais capables de deceler la moindre alteration de sequence dans les portions essentielles des genes. La detections de mutations est une demarche complexe et aucune des methodes disponibles n'est applicable seule a toutes les situations, leur choix dependant de nombreux criteres (nature des mutations, taille et structures du gene, acces a l'ARNm, degres d'efficacite et de sensibilite recherches). Nous presentons les avantages relatifs d'une strategie de recherche specifique des mutations qui introduisent un signal d'arret premature de la synthese proteique, fondee sur le test de troncation des proteines (PTT), par rapport aux techniques classiques de balayage d'un fragment d'ADN ou d'ARN telles que l'electrophores en gel de gradient denaturant (DGGE), l'analyse d'heteroduplex (HA), l'analyse de conformation de l'ADN en simple brin (SSCA) ou le clivage chimique ou enzymatique de mesappariements (CCM/EMC). Le PTT, fonde sur l'analyse de fragments d'ARN ou d'ADN transcrits et traduits in vitro, parait etre, pour certaines maladies genetiques, la facon la plus efficace et la moins couteuse de deceler les mutations de l'ADN responsables de troncation proteique.
- Published
- 1998
- Full Text
- View/download PDF
32. Anthracycline as second line chemotherapy (CT) for metastatic breast cancer (MBC) patients previously treated with taxotere (TXT)
- Author
-
C. Maugard, F. Priou, Geneviève Perrocheau, Pierre Fumoleau, R. Fety, A. Riva, V. Delecroix, N. Azli, and B. Lemevel
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Anthracycline ,business.industry ,Internal medicine ,Medicine ,business ,medicine.disease ,Previously treated ,Metastatic breast cancer ,Second line chemotherapy - Published
- 1997
- Full Text
- View/download PDF
33. Souffrance endothéliale et voie du facteur tissulaire dans l'insuffisance rénale chronique
- Author
-
M Ramuz, S Brun, B. Branger, R. Oules, J. Fourcade, Jean-Christophe Gris, F. Vecina, B. Al. Sabadani, and C Maugard
- Subjects
business.industry ,Gastroenterology ,Internal Medicine ,Medicine ,business - Published
- 1997
- Full Text
- View/download PDF
34. 970 An evaluation of the neurotoxicity of a phase I dose finding study of docetaxel (D) in combination with vinorelbin (V)
- Author
-
N. Azli, J.P. Louboutin, V. Delecroix, M. Gentin, C. Maugard-Louboutin, Geneviève Perrocheau, and Pierre Fumoleau
- Subjects
Cancer Research ,Pathology ,medicine.medical_specialty ,Combination therapy ,business.industry ,Neurotoxicity ,Urology ,Cancer ,Motor nerve ,Vinorelbine ,medicine.disease ,Metastatic breast cancer ,Nerve conduction velocity ,Oncology ,Docetaxel ,medicine ,business ,medicine.drug - Abstract
D, belonging to the taxoid class of anticancer agents, enhances microtubule assembly and inhibits the depolymerization of tubulin. The cytotoxic activity of V is through inhibition of the microtubule assembly. D and V have both shown clinical activity in advanced breast cancer as single agent. Additionally, therapeutic synergism has been observed in preclinical studies when the two drugs are combined simultaneously. Thus, a phase I study of a combination of these 2 drugs commenced in patients with metastatic breast cancer. However, as D. and V. induce mild neurotoxicity, neurological effects of this combination were evaluated. Neurological function at baseline, during (every 2 cycles and at the end of the study), and following treatment, in 13 metastatic breast cancer patients treated with docetaxel (60–85 mg/m2) and vinorelbine (20–22.5 mg/m2—D1–D5), none of them treated with vinca-alcaloids and/or CDDP, were prospectively evaluated. Deep tendon reflexes decrease was the most frequent abnormal finding, which occurred in 10 patients (77%). Mild, temporary and reversible grade 1 asymptomatic paresthesia were seen in 4 patients (31%). Pin sensibility, vibration sensation and muscular strength were always normal. Median and peroneal motor nerve conduction velocities, as well as median sensitive nerve conduction velocity, remained in the normal ranges. Peripheral neurotoxicity induced by the docetaxel-vinorelbine combination therapy appears to be mild (grade 1 according to NCI toxicity criteria).
- Published
- 1995
- Full Text
- View/download PDF
35. Study of 2 doses of granulocyte colony stimulating factor (G-CSF): PE 2601 in patients (PTS) with advanced breast carcinoma (ABC) treated by intensive chemotherapy
- Author
-
M. Delgado, P. Tresca, Henri Roché, C. Maugard-Louboutin, C. Chastang, Pierre Kerbrat, B. Chevallier, and Pierre Fumoleau
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,Advanced breast ,Intensive chemotherapy ,medicine.disease ,Granulocyte colony-stimulating factor ,Internal medicine ,medicine ,Carcinoma ,In patient ,business - Published
- 1993
- Full Text
- View/download PDF
36. Preliminary phase II trial of oxaliplatin (L-OHP) in malignant astrocytomas
- Author
-
C. Maugard-Louboutin, D. Menegalli-Boggelli, Y. Lajat, Pierre Fumoleau, N. Ibrabim, J. Gastiaburu, F. Resche, S. Brienza, and S. Bourdin
- Subjects
Cancer Research ,Oncology ,business.industry ,Phase (matter) ,Cancer research ,Medicine ,business ,Oxaliplatin ,medicine.drug - Published
- 1993
- Full Text
- View/download PDF
37. Giant cell arteritis in a conjugal pair
- Author
-
J H, Barrier, J M, Brisseau, V, Lucas, C, Maugard-Louboutin, J, Groleau, and J Y, Grolleau
- Subjects
Male ,Giant Cell Arteritis ,Humans ,Female ,Marriage ,Aged - Published
- 1988
38. Time elapsing from cancer diagnosis and anxiety in women attending cancer genetic clinics
- Author
-
Hagay Sobol, P. Vennin, Y. Aurran, François Eisinger, M. Machelard, Claire Julian-Reynier, Catherine Noguès, Y J Bignon, C. Maugard, and Françoise Chabal
- Subjects
Cancer Research ,medicine.medical_specialty ,Time Factors ,Anxiety states ,Genetic counseling ,media_common.quotation_subject ,Breast Neoplasms ,Genetic Counseling ,Anxiety ,Fight-or-flight response ,Surveys and Questionnaires ,medicine ,Humans ,media_common ,Ovarian Neoplasms ,business.industry ,Cancer ,General Medicine ,Middle Aged ,medicine.disease ,Surgery ,Oncology ,Feeling ,Family medicine ,Anxiety score ,Regression Analysis ,Female ,France ,medicine.symptom ,business ,Ovarian cancer - Abstract
The aim of this study was to investigate the effects of cancer genetic consultations on feelings of anxiety in women with breast/ovarian cancer. Among the 138 women attending six French clinics during a one-year period, 115 (83.3%) answered pre- and post-consultation questionnaires. The state anxiety score (Spielberger's STAI) was lower (paired t-test, p
39. A pilot rating system to evaluate the quality of goal attainment scales used as outcome measures in rehabilitation.
- Author
-
Pradeau C, Estival S, Postal V, Laurier V, Maugard C, Isner-Horobeti ME, Mourre F, and Krasny-Pacini A
- Abstract
Goal Attainment Scaling (GAS) is a method for writing person-centred approach evaluation scales that can be used as an outcome measure in clinical or research settings in rehabilitation. To be used in a research setting, it requires a high methodological quality approach. The aim of this study was to explore the feasibility and reliability of the GAS quality rating system, to ensure that GAS scales used as outcome measures are valid and reliable. Secondary objectives were: (1) to compare goal attainment scores' reliability according to how many GAS levels are described in the scale; and (2) to explore if GAS scorings are influenced by who scores goal attainment. The GAS scales analysed here were set collaboratively by 57 cognitively impaired adults clients and their occupational therapist. Goals had to be achieved within an inpatient one-month stay, during which clients participated in an intervention aimed at improving planning skills in daily life. The GAS quality rating system proved to be feasible and reliable. Regarding GAS scores, interrater reliability was higher when only three of the five GAS levels were described, i.e., "three milestone GAS" (0.74-0.92), than when all five levels were described (0.5-0.88), especially when scored by the clients (0.5 -0.88).
- Published
- 2024
- Full Text
- View/download PDF
40. Seven years (2015-2021) of blood donor screening for HEV-RNA in France: lessons and perspectives.
- Author
-
Laperche S, Maugard C, Lhomme S, Lecam S, Ricard C, Dupont I, Richard P, Tiberghien P, Abravanel F, Morel P, Izopet J, and Gallian P
- Subjects
- Humans, Blood Platelets, RNA, Viral, France, Blood Donors, Donor Selection, Blood Component Removal
- Abstract
Background: The French health authorities are considering expanding the current selective hepatitis E virus (HEV)-RNA testing procedure to include all donations in order to further reduce transfusion-transmitted HEV infection. Data obtained from blood donors (BDs) tested for HEV-RNA between 2015 and 2021 were used to assess the most efficient nucleic acid testing (NAT) strategy., Materials and Methods: Viral loads (VLs) and the plasma volume of blood components, as well as an HEV-RNA dose of 3.85 log IU as the infectious threshold and an assay with a 95% limit of detection (LOD) at 17 IU/mL, were used to assess the proportion of: (i) HEV-RNA-positive BDs that would remain undetected; and (ii) blood components associated with these undetected BDs with an HEV-RNA dose >3.85 log IU, considering 4 NAT options (Individual testing [ID], MP-6, MP-12, and MP-24)., Results: Of the 510,118 BDs collected during the study period, 510 (0.10%) were HEV-RNA-positive. Based on measurable VLs available in 388 cases, 1%, 15.2%, 21.8%, and 32.6% of BDs would theoretically pass undetected due to a VL below the LOD of ID, MP-6, MP-12, and MP-24 testing, respectively. All BDs associated with a potentially infectious blood component would be detected with ID-NAT while 13% of them would be undetected with MP-6, 19.6% with MP-12, and 30.4% with MP-24 depending on the plasma volume. No red blood cell (RBC) components with an HEV-RNA dose >3.85 log IU would enter the blood supply, regardless of the NAT strategy used., Discussion: A highly sensitive ID-NAT would ensure maximum safety. However, an MP-based strategy can be considered given that: (i) the risk of transmission is closely related to the plasma volume of blood components; (ii) RBC are the most commonly transfused components and have a low plasma content; and (iii) HEV-RNA doses transmitting infection exceed 4 log IU. To minimise the potential risk associated with apheresis platelet components and fresh frozen plasma, less than 12 donations should be pooled using an NAT assay with a LOD of approximately 20 IU/mL.
- Published
- 2023
- Full Text
- View/download PDF
41. Risk of a blood donation contaminated with hepatitis E virus entering the blood supply before the implementation of universal RNA screening in France.
- Author
-
Pillonel J, Maugard C, Sommen C, Figoni J, Pierre C, LeCam S, Richard P, Morel P, Gallian P, and Laperche S
- Subjects
- Male, Female, Humans, Blood Donation, Blood Donors, RNA, Viral, Hepatitis E virus genetics, Hepatitis E diagnosis, Hepatitis E epidemiology
- Abstract
Background and Objectives: The risk of a blood donation contaminated with hepatitis E virus (HEV) entering the blood supply before introducing universal HEV-RNA screening in France was estimated to assess the benefit of such a measure., Materials and Methods: The results of selective HEV nucleic acid testing (HEV-NAT) performed in mini pool of six plasma donations between 2018 and 2020 were extrapolated to the whole blood donor (BD) population after adjustment on three variables: regional establishment, sex and age group., Results: Among the 246,285 plasma donations collected from 172,635 BDs tested for HEV-RNA, 248 (10.1/10,000) were positive. The extrapolation to all BDs led to an estimated rate of 5.9/10,000 donations (95% confidence interval [CI]: 4.5-7.4) which would be positive to HEV-RNA and a prevalence of 9.9/10,000 BDs (95% CI: 7.5-12.3). This prevalence was 4.4 times higher in males than females (16.8/10,000 vs. 3.8/10,000, p < 10
-4 ). The highest prevalence was observed in males in the 30-39 age group (20.5/10,000) and the lowest in females in the 50-70 age group (2.8/10,000)., Conclusion: The risk of an HEV-RNA-positive donation entering the blood supply was estimated at 1 in 1682 donations. This risk does not translate directly to the risk of HEV transfusion transmission, which mainly depends on the total number of viral particles in the transfused blood component and the sensitivity of NAT., (© 2022 International Society of Blood Transfusion.)- Published
- 2022
- Full Text
- View/download PDF
42. Insights on 21 Years of HBV Surveillance in Blood Donors in France.
- Author
-
Cappy P, Boizeau L, Candotti D, Le Cam S, Martinaud C, Pillonel J, Tribout M, Maugard C, Relave J, Richard P, Morel P, and Laperche S
- Subjects
- Humans, Blood Donors, DNA, Viral genetics, Hepatitis B Antibodies, Hepatitis B Surface Antigens, Hepatitis B virus genetics, Hepatitis B diagnosis
- Abstract
Hepatitis B virus (HBV) infection is the most frequent viral infection found in blood donors (BDs) in France. We analyzed the epidemiological and sero-molecular data on HBV infection gathered over the past two decades by the French haemovigilance surveillance network, blood screening laboratories, and the national reference center for transfusion infectious risks (NRC). Between 2000 and 2020, 6149 of the 58,160,984 donations (1.06/10,000) tested HBV positive, 98% of them from first-time blood donors (FTBDs). In addition, 2212 (0.0071%) of the 30,977,753 donations screened for HBV DNA tested DNA positive, of which 25 (1.1%) were positive only for this marker. HBV prevalence decreased by 2.8-fold and the residual risk for transfusion-transmitted HBV infection decreased 13-fold and was divided by 13. The major risk factor for HBV infection was the origin of donors (endemic country, 66.5%), followed by parenteral exposure (10.7%). In the whole HBV-positive BD population, genotype D was predominant (41.8%), followed by genotypes A (26.2%) and E (20.4%), reflecting the geographical origin of donors. The low and decreasing prevalence and incidence of HBV infection in French BDs, coupled with a screening strategy using three HBV markers (HBsAg, anti-HBc and DNA), ensures a high level of blood safety, further reinforced by the implementation of pathogen-reduction measures.
- Published
- 2022
- Full Text
- View/download PDF
43. The TRACTOR Project: TRACking and MoniToring Occupational Risks in Agriculture Using French Insurance Health Data (MSA).
- Author
-
Petit P, Bosson-Rieutort D, Maugard C, Gondard E, Ozenfant D, Joubert N, François O, and Bonneterre V
- Subjects
- Agriculture, Farmers, Humans, Prospective Studies, Insurance, Occupational Exposure
- Abstract
Objectives: A vast data mining project called 'TRACking and moniToring Occupational Risks in agriculture' (TRACTOR) was initiated in 2017 to investigate work-related health events among the entire French agricultural workforce. The goal of this work is to present the TRACTOR project, the challenges faced during its implementation, to discuss its strengths and limitations and to address its potential impact for health surveillance., Methods: Three routinely collected administrative health databases from the National Health Insurance Fund for Agricultural Workers and Farmers (MSA) were made available for the TRACTOR project. Data management was required to properly clean and prepare the data before linking together all available databases., Results: After removing few missing and aberrant data (4.6% values), all available databases were fully linked together. The TRACTOR project is an exhaustive database of agricultural workforce (active and retired) from 2002 to 2016, with around 10.5 million individuals including seasonal workers and farm managers. From 2012 to 2016, a total of 6 906 290 individuals were recorded. Half of these individuals were active and 46% had at least one health event (e.g. declared chronic disease, reimbursed drug prescription) during this 5-year period., Conclusions: The assembled MSA databases available in the TRACTOR project are regularly updated and represent a promising and unprecedent dataset for data mining analysis dedicated to the early identification of current and emerging work-related illnesses and hypothesis generation. As a result, this project could help building a prospective integrated health surveillance system for the benefit of agricultural workers., (© The Author(s) 2021. Published by Oxford University Press on behalf of the British Occupational Hygiene Society.)
- Published
- 2022
- Full Text
- View/download PDF
44. Low rate of RNAemia in blood donations collected during the first wave of COVID-19 in France.
- Author
-
Le Cam S, Gallian P, Ricard C, Narboux C, Barlet V, Maugard C, Hauser L, Brisbarre N, Cappy P, Pillonel J, Laperche S, and Morel P
- Subjects
- Humans, RNA, Viral, Retrospective Studies, SARS-CoV-2, Blood Donors, COVID-19 epidemiology
- Abstract
Background: To investigate the transmission of SARS-CoV-2 via blood, we conducted retrospective molecular screening in blood donated during the first pandemic peak in the two French regions with the highest community transmission., Methods: Archived plasma samples randomly selected from donations collected between March 23 and 29, 2020, in Eastern and Northern regions of France were tested for SARS-CoV-2 RNA in minipools of 4 donations (MP4) using the Grifols ProcleixSARS-CoV-2 assay. Reactive MP4 and the four corresponding plasmas were further tested with alternative RT-PCRs and sequencing. Testing for SARS-CoV-2 antibodies and in vitro infectivity in cell culture were also performed., Results: Among the 2818 MP4 (corresponding to 9672 donations) tested for viral RNA, 5 were weakly reactive. Among the 20 plasmas included in these five MP4, one presented low-level reactivity with RT-PCRs and Procleix SARS-CoV-2 and was confirmed on sequencing. The estimated prevalence was 1.03/10,000 (95% CI 0-3.1). The 20 plasmas were antibody nonreactive and none of them showed cytopathic effects in cell culture. When recalled, the index-donor declared having had symptoms compatible with SARS-CoV-2 infection a few days after donation. The two immunocompromised recipients transfused with red blood cells and an inactivated pooled platelet product did not develop COVID-19., Conclusion: Our results indicated a low prevalence of SARS-CoV-2 RNA in the plasma of asymptomatic blood donors during the pandemic peak and no evidence of infectivity in vivo and in vitro. The transfusion risk remains theoretical and does not justify the implementation of SARS-CoV-2 NAT for blood donations., (© 2022 AABB.)
- Published
- 2022
- Full Text
- View/download PDF
45. Novel germline MET pathogenic variants in French patients with papillary renal cell carcinomas type I.
- Author
-
Sebai M, Tulasne D, Caputo SM, Verkarre V, Fernandes M, Guérin C, Reinhart F, Adams S, Maugard C, Caron O, Guillaud-Bataille M, Berthet P, Bignon YJ, Bressac-de Paillerets B, Burnichon N, Chiesa J, Giraud S, Lejeune S, Limacher JM, de Pauw A, Stoppa-Lyonnet D, Zattara-Cannoni H, Deveaux S, Lidereau R, Richard S, and Rouleau E
- Subjects
- Female, Germ Cells metabolism, Humans, Male, Phenotype, Carcinoma, Renal Cell genetics, Kidney Neoplasms genetics, Neoplastic Syndromes, Hereditary, Proto-Oncogene Proteins c-met genetics
- Abstract
Hereditary papillary renal cell carcinoma (HPRC) is a rare inherited renal cancer syndrome characterized by bilateral and multifocal papillary type 1 renal tumors (PRCC1). Activating germline pathogenic variants of the MET gene were identified in HPRC families. We reviewed the medical and molecular records of a large French series of 158 patients screened for MET oncogenic variants. MET pathogenic and likely pathogenic variants rate was 12.4% with 40.6% among patients with familial PRCC1 and 5% among patients with sporadic PRCC1. The phenotype in cases with MET pathogenic and likely pathogenic variants was characteristic: PRCC1 tumors were mainly bilateral (84.3%) and multifocal (87.5%). Histologically, six out of seven patients with MET pathogenic variant harbored biphasic squamoid alveolar PRCC. Genetic screening identified one novel pathogenic variant MET c.3389T>C, p.(Leu1130Ser) and three novel likely pathogenic variants: MET c.3257A>T, p.(His1086Leu); MET c.3305T>C, p.(Ile1102Thr) and MET c.3373T>G, p.(Cys1125Gly). Functional assay confirmed their oncogenic effect as they induced an abnormal focus formation. The genotype-phenotype correlation between MET pathogenic variants and PRCC1 presentation should encourage to widen the screening, especially toward nonfamilial PRCC1. This precise phenotype also constitutes a strong argument for the classification of novel missense variants within the tyrosine kinase domain when functional assays are not accessible., (© 2021 Wiley Periodicals LLC.)
- Published
- 2022
- Full Text
- View/download PDF
46. [Techniques and complications of non-genetic risk reducing mastectomies: Guidelines of the National College of French Gynecologists and Obstetricians (CNGOF)].
- Author
-
Mathelin C, Barranger E, Boisserie-Lacroix M, Boutet G, Brousse S, Chabbert-Buffet N, Coutant C, Daraï E, Delpech Y, Duraes M, Espié M, Golfier F, Hamy AS, Kermarrec E, Lavoué V, Lodi M, Luporsi É, Maugard C, Molière S, Seror JY, Taris N, Uzan C, Vaysse C, and Fritel X
- Subjects
- Educational Status, Humans, Mastectomy
- Abstract
Objective: Based on an updated review of the international literature covering the different surgical techniques and complications of risk reducing mastectomies (RRM) in non-genetic context, the Commission of Senology (CS) of the College National des Gynécologues Obstétriciens Français (CNGOF) aimed to establish recommendations on the techniques to be chosen and their implementation., Design: The CNGOF CS, composed of 24 experts, developed these recommendations. A policy of declaration and monitoring of links of interest was applied throughout the process of making the recommendations. Similarly, the development of these recommendations did not benefit from any funding from a company marketing a health product. The CS adhered to and followed the AGREE II (Advancing guideline development, reporting and evaluation in healthcare) criteria and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) method to assess the quality of the evidence on which the recommendations were based. The potential drawbacks of making recommendations in the presence of poor quality or insufficient evidence were highlighted., Methods: The CS considered 6 questions in 4 thematic areas, focusing on oncologic safety, risk of complications, aesthetic satisfaction and psychological impact, and preoperative modalities., Results: The application of the GRADE method resulted in 7 recommendations, 6 with a high level of evidence (GRADE 1±) and 1 with a low level of evidence (GRADE 2±)., Conclusion: There was significant agreement among the CS members on recommendations for preferred surgical techniques and practical implementation., (Copyright © 2021 Elsevier Masson SAS. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
47. Clinical performance evaluation of Elecsys HIV Duo, Anti-HCV II, HBsAg II, Anti-HBc II, and Syphilis assays for routine screening of first-time blood donor samples at a French blood donation center.
- Author
-
Maugard C, Relave J, Klinkicht M, and Fabra C
- Subjects
- Blood Donors, Hepatitis B Surface Antigens, Humans, Sensitivity and Specificity, HIV Infections diagnosis, Hepatitis B diagnosis, Syphilis diagnosis
- Abstract
Objectives: Implementing fully automated analyzers has become a crucial safety step in blood donation centers. The Elecsys® assays were evaluated on the cobas e 801 module (Roche Diagnostics) for routine first-time blood donor screening., Materials & Methods: Five Elecsys infectious disease assays were tested on the cobas e 801 module at Etablissement Français du Sang, Montpellier, France (March-April 2018). The performance of Elecsys HIV Duo, Anti-HCV II, HBsAg II, Anti-HBc II, and Syphilis assays was compared with PRISM HIV O Plus, HCV, HBsAg, HBcore, and newbio pk TPHA assays (specificity analyses)/ARCHITECT Syphilis TP (sensitivity analyses), respectively. Specificity was determined in residual fresh serum samples from unselected first-time blood donors (n≥5195 per parameter). Elecsys assay sensitivity was tested using 30 preselected, positively characterized samples per assay and compared with archived routine testing data for comparator assays., Results: Across all parameters, specificities for repeatedly reactive samples ranged from 99.81-100.00% for Elecsys assays and 99.71-99.98% for comparator assays. Sensitivities of Elecsys and comparator assays were the same for hepatitis C (85.19%), hepatitis B surface antigen (70.00%), hepatitis B core antigen antibodies (100.00%), and syphilis (100.00%). The sensitivity of the Elecsys HIV Duo assay was higher than the comparator assay (83.33% vs. 76.67%), but the difference was not statistically significant., Conclusions: Elecsys infectious disease assays on the cobas e 801 module demonstrated high specificity and sensitivity for screening first-time blood donor samples, and were comparable with other commercially available assays. The Elecsys assays are reliable tests for screening blood donations., (Copyright © 2021 Société française de transfusion sanguine (SFTS). Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
48. Classification of 101 BRCA1 and BRCA2 variants of uncertain significance by cosegregation study: A powerful approach.
- Author
-
Caputo SM, Golmard L, Léone M, Damiola F, Guillaud-Bataille M, Revillion F, Rouleau E, Derive N, Buisson A, Basset N, Schwartz M, Vilquin P, Garrec C, Privat M, Gay-Bellile M, Abadie C, Abidallah K, Airaud F, Allary AS, Barouk-Simonet E, Belotti M, Benigni C, Benusiglio PR, Berthemin C, Berthet P, Bertrand O, Bézieau S, Bidart M, Bignon YJ, Birot AM, Blanluet M, Bloucard A, Bombled J, Bonadona V, Bonnet F, Bonnet-Dupeyron MN, Boulaire M, Boulouard F, Bouras A, Bourdon V, Brahimi A, Brayotel F, Bressac de Paillerets B, Bronnec N, Bubien V, Buecher B, Cabaret O, Carriere J, Chiesa J, Chieze-Valéro S, Cohen C, Cohen-Haguenauer O, Colas C, Collonge-Rame MA, Conoy AL, Coulet F, Coupier I, Crivelli L, Cusin V, De Pauw A, Dehainault C, Delhomelle H, Delnatte C, Demontety S, Denizeau P, Devulder P, Dreyfus H, d'Enghein CD, Dupré A, Durlach A, Dussart S, Fajac A, Fekairi S, Fert-Ferrer S, Fiévet A, Fouillet R, Mouret-Fourme E, Gauthier-Villars M, Gesta P, Giraud S, Gladieff L, Goldbarg V, Goussot V, Guibert V, Guillerm E, Guy C, Hardouin A, Heude C, Houdayer C, Ingster O, Jacquot-Sawka C, Jones N, Krieger S, Lacoste S, Lallaoui H, Larbre H, Laugé A, Le Guyadec G, Le Mentec M, Lecerf C, Le Gall J, Legendre B, Legrand C, Legros A, Lejeune S, Lidereau R, Lignon N, Limacher JM, Doriane Livon, Lizard S, Longy M, Lortholary A, Macquere P, Mailliez A, Malsa S, Margot H, Mari V, Maugard C, Meira C, Menjard J, Molière D, Moncoutier V, Moretta-Serra J, Muller E, Nevière Z, Nguyen Minh Tuan TV, Noguchi T, Noguès C, Oca F, Popovici C, Prieur F, Raad S, Rey JM, Ricou A, Salle L, Saule C, Sevenet N, Simaga F, Sobol H, Suybeng V, Tennevet I, Tenreiro H, Tinat J, Toulas C, Turbiez I, Uhrhammer N, Vande Perre P, Vaur D, Venat L, Viellard N, Villy MC, Warcoin M, Yvard A, Zattara H, Caron O, Lasset C, Remenieras A, Boutry-Kryza N, Castéra L, and Stoppa-Lyonnet D
- Subjects
- Breast Neoplasms classification, Breast Neoplasms genetics, Female, Genetic Testing, Genotype, Humans, Ovarian Neoplasms classification, Ovarian Neoplasms genetics, BRCA1 Protein genetics, BRCA2 Protein genetics, Breast Neoplasms pathology, Genetic Predisposition to Disease, Genetic Variation, Ovarian Neoplasms pathology
- Abstract
Up to 80% of BRCA1 and BRCA2 genetic variants remain of uncertain clinical significance (VUSs). Only variants classified as pathogenic or likely pathogenic can guide breast and ovarian cancer prevention measures and treatment by PARP inhibitors. We report the first results of the ongoing French national COVAR (cosegregation variant) study, the aim of which is to classify BRCA1/2 VUSs. The classification method was a multifactorial model combining different associations between VUSs and cancer, including cosegregation data. At this time, among the 653 variants selected, 101 (15%) distinct variants shared by 1,624 families were classified as pathogenic/likely pathogenic or benign/likely benign by the COVAR study. Sixty-six of the 101 (65%) variants classified by COVAR would have remained VUSs without cosegregation data. Of note, among the 34 variants classified as pathogenic by COVAR, 16 remained VUSs or likely pathogenic when following the ACMG/AMP variant classification guidelines. Although the initiation and organization of cosegregation analyses require a considerable effort, the growing number of available genetic tests results in an increasing number of families sharing a particular variant, and thereby increases the power of such analyses. Here we demonstrate that variant cosegregation analyses are a powerful tool for the classification of variants in the BRCA1/2 breast-ovarian cancer predisposition genes., Competing Interests: Declaration of interests D.S.-L. and the Institut Curie have received honoraria for her participation in education meetings organized by AstraZeneca or Tesaro. The remaining authors declare no conflict of interest., (Copyright © 2021 American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
49. Preventing transfusion-transmitted malaria in France.
- Author
-
Le Cam S, Houze S, Barlet V, Maugard C, Narboux C, Morel P, Garraud O, Tiberghien P, and Gallian P
- Subjects
- Blood Transfusion, France epidemiology, Humans, Malaria epidemiology, Malaria prevention & control
- Published
- 2021
- Full Text
- View/download PDF
50. National recommendations of the French Genetics and Cancer Group - Unicancer on the modalities of multi-genes panel analyses in hereditary predispositions to tumors of the digestive tract.
- Author
-
Dhooge M, Baert-Desurmont S, Corsini C, Caron O, Andrieu N, Berthet P, Bonadona V, Cohen-Haguenauer O, De Pauw A, Delnatte C, Dussart S, Lasset C, Leroux D, Maugard C, Moretta-Serra J, Popovici C, Buecher B, Colas C, and Noguès C
- Subjects
- Academies and Institutes standards, Biomarkers, Tumor standards, France, Gastrointestinal Neoplasms diagnosis, Humans, Biomarkers, Tumor genetics, Gastrointestinal Neoplasms genetics, Genetic Testing standards, Practice Guidelines as Topic
- Abstract
In case of suspected hereditary predisposition to digestive cancers, next-generation sequencing can analyze simultaneously several genes associated with an increased risk of developing these tumors. Thus, "Gastro Intestinal" (GI) gene panels are commonly used in French molecular genetic laboratories. Lack of international recommendations led to disparities in the composition of these panels and in the management of patients. To harmonize practices, the Genetics and Cancer Group (GGC)-Unicancer set up a working group who carried out a review of the literature for 31 genes of interest in this context and established a list of genes for which the estimated risks associated with pathogenic variant seemed sufficiently reliable and high for clinical use. Pancreatic cancer susceptibility genes have been excluded. This expertise defined a panel of 14 genes of confirmed clinical interest and relevant for genetic counseling: APC, BMPR1A, CDH1, EPCAM, MLH1, MSH2, MSH6, MUTYH, PMS2, POLD1, POLE, PTEN, SMAD4 and STK11. The reasons for the exclusion of the others 23 genes have been discussed. The paucity of estimates of the associated tumor risks led to the exclusion of genes, in particular CTNNA1, MSH3 and NTHL1, despite their implication in the molecular pathways involved in the pathophysiology of GI cancers. A regular update of the literature is planned to up-grade this panel of genes in case of new data on candidate genes. Genetic and epidemiological studies and international collaborations are needed to better estimate the risks associated with the pathogenic variants of these genes either selected or not in the current panel., (Copyright © 2020 Elsevier Masson SAS. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.